
POU2F1

SEQUENCING OF A CANDIDATE GENE FOR HEREDITARY HEARING IMPAIRMENT

**By Stud. Med. Garth Tylden
Supervised by Toril Fagerheim**



A 5th year research thesis

Faculty of Medicine, University of Tromsø

Written at the Department of Medical Genetics, University Hospital of North Norway/

Institute of Clinical Medicine, University of Tromsø

June - September 2003



ACKNOWLEDGEMENTS.....	2
GLOSSARY.....	3
SUMMARY	4
INTRODUCTION.....	5
INCIDENCE OF HEARING LOSS	5
GENETICS OF HEARING IMPAIRMENT	5
NON-SYNDROMIC AUTOSOMAL DOMINANT DEAFNESS LOCUS NUMBER 7 (<i>DFNA7</i>)	5
POU DOMAIN CLASS 2 TRANSCRIPTION FACTOR 1; <i>POU2F1</i>	6
MATERIAL AND METHODS.....	8
CLINICAL MATERIAL	8
ACQUISITION OF THE CONSENSUS SEQUENCE AND PRIMER DESIGN	9
<i>Exon and intron primers.</i>	9
TEMPLATE ACQUISITION	12
<i>Isolation of genomic DNA.</i>	12
<i>Synthesis of cDNA</i>	12
AUTOMATIC SEQUENCING.....	13
<i>PCR</i>	13
<i>Electrophoresis</i>	14
<i>Cleaning the PCR product.</i>	15
<i>Sequencing</i>	15
<i>Precipitation of the sequencing product</i>	15
<i>Sequencing electrophoresis</i>	16
<i>Sequence analysis</i>	16
RESULTS AND DISCUSSION.....	17
ACQUISITION OF THE CONSENSUS SEQUENCE AND PRIMER DESIGN	17
<i>Testing of primers.</i>	18
AUTOMATIC SEQUENCING	19
<i>PCR</i>	19
<i>Subject DNA</i>	19
<i>cDNA</i>	21
SEQUENCING	23
<i>Subject DNA</i>	23
<i>cDNA</i>	23
CONCLUSION.....	24
REFERENCES.....	25
APPENDIX	26

Acknowledgements

This research thesis was executed at the Department of Medical Genetics at the University Hospital of Northern Norway (UNN) during the spring and summer of 2003.

Firstly, I would like to thank my supervisor Toril Fagerheim for her informal, enthusiastic guidance and her ability to not appear condescending in the face of stupid questions.

A special thanks to Bo Dreyer for his invaluable contributions, to Øivind Nilssen, Vigdis Brox and Helle Klenow for their help and insights and to Mona Nystad, Bente Guntvedt and Christoffer Jonsrud for giving me a glimpse of other aspects of every day life at DMG UNN.

Finally, I would like to thank all the members of the department for generating the positive atmosphere that made this undertaking a pleasurable learning experience.

Glossary

Caloric testing	A test for vestibular function, made by irrigating the external auditory meatus with either hot or cold water; this normally causes stimulation of the vestibular apparatus, resulting in nystagmus; in vestibular disease, the response may be reduced or absent.
cDNA (complementary DNA)	DNA that is synthesized <i>in vitro</i> from a messenger RNA template that corresponds to expressed sequences of genomic DNA. Viral reverse transcriptase is used to synthesize cDNA.
cM (centimorgan)	A unit of measure of recombination frequency. One centimorgan is equal to a 1% chance that a marker at one genetic locus will be separated from a marker at a second locus due to crossing over in a single generation. In human beings, 1 centimorgan is equivalent, on average, to 1 million base pairs.
<i>DFNA7</i>	Autosomal dominant non-syndromic deafness locus number 7. The letter A indicates dominant pattern of inheritance. Recessive loci are denoted <i>DFNB</i> .
Exon	A coding sequence of DNA within a gene, which survives the processing of RNA in the cell nucleus to become part of a spliced messenger RNA in the cytoplasm. In the primary RNA transcript neighbouring exons are separated by introns.
Intron	A noncoding sequence of DNA within a gene, that is transcribed into the primary RNA transcript but is then cut out by RNA splicing, leaving a mature mRNA that is then translated in the cytoplasm.
Locus	Introns are poorly conserved and of variable length, but the regions at the ends are self complementary, allowing a hairpin structure to form naturally in the hnRNA, this is the cue for removal by RNA splicing. Introns are thought to play an important role in allowing rapid evolution of proteins by exon shuffling.
Lod score	The site in a linkage map or on a chromosome where the gene/marker is located. Any one of the alleles of a gene may be present at this site.
Microsatellite markers	The total relative probability, expressed on a logarithmic scale, that a linkage relationship exists among selected loci. Lod is an acronym for "logarithmic odds."
PCR (polymerase chain reaction)	Small repetitive DNA sequences dispersed in genomes. The lengths of these elements are hyper-variable and thus are highly polymorphic, making them ideal in genomic fingerprinting applications
Presbyacusis	The first practical system for <i>in vitro</i> amplification of DNA and as such one of the most important recent developments in molecular biology.
Primer	Two synthetic oligonucleotide primers, which are complementary to two regions of the target DNA (one for each strand) to be amplified, are added to the target DNA (that need not be pure), in the presence of excess deoxynucleotides and Taq polymerase, a heat stable DNA polymerase. In a series (typically 30) of temperature cycles, the target DNA is repeatedly denatured (around 90°C), annealed to the primers (typically at 50-60°C) and a daughter strand extended from the primers (72°C). As the daughter strands themselves act as templates for subsequent cycles, DNA fragments matching both primers are amplified exponentially, rather than linearly.
SSCP analysis	The original DNA need thus be neither pure nor abundant and the polymerase chain reaction has accordingly become widely used not only in research, but in clinical diagnostics and forensic science.
Transcript	Loss of ability to perceive or discriminate sounds as a part of the aging process.
Transcription factor	Short pre-existing polynucleotide chain to which new deoxyribonucleotides can be added by DNA polymerase.
	Single stranded conformational polymorphism analysis
	Technique for detecting point mutations in genes by amplifying a region of genomic DNA (using asymmetric PCR) and running the resulting product on a high quality gel. Single base substitutions can alter the secondary structure of the fragment in the gel, producing a visible shift in its mobility.
	Term used to refer to the various segments of messenger RNA (mRNA) that result from transcription of a gene.
	Protein required by RNA polymerase for activation of transcription of eukaryotic genes. Binds to promoter region upstream from the activated gene.

Summary

Hearing impairment (HI) is the most common sensory debility. In developed countries prelingual HI affects about 1 in 1000 children. Genetics plays an important role in congenital HI and doubtlessly also in presbyacusis. The HI locus *DFNA7* was mapped by Fagerheim et al in a large Norwegian family where affected individuals exhibit non-syndromic autosomal dominant post lingual progressive high-tone hearing loss. The locus spans a 22 cM region between the microsatellite markers D1S104 and D1S466 on chromosome 1 (1q21-q23). Within this region, only 0.8-cM from the D1S196 marker which gave the highest lod-score, lies the *POU2F1* gene. *POU2F1* encodes a ubiquitously expressed transcription factor and is one of several candidate genes in the *DFNA7* locus. *POU2F1* belongs to the POU domain family of transcription factors, 2 of which have earlier been shown to cause nonsyndromic HI. In this study, the genomic structure of *POU2F1* was deduced using different genomic databases. The gene consisted of 21 exons which, according to sequence information listed at ENSEMBLE, gave rise to 5 transcripts varying from 2-17 exons in length. The purpose of the study was to identify potential mutations, so although some exons were less well documented than others, all 21 exons were sequenced. The template DNA was the genomic DNA of 2 affected and 2 unaffected members of the Norwegian family mentioned above. Additionally *POU2F1* cDNA from a healthy donor was sequenced to control the consensus sequence data. There were no apparent differences between affected and unaffected subjects. However, one difference between the subject DNA and the consensus sequence was found, namely a single G>C substitution at position 143 in exon 2. The substitution was shared by all 4 subjects and thus probably represents a polymorphism. Unfortunately, no cDNA sequence data was obtained covering exon 2 for comparison. No information regarding single nucleotide polymorphisms in this exon was available at the NCBI database and as such, we have no inkling of the frequency of this polymorphism.

cDNA sequences were resolved covering exons 1 and 6-21, evidence was also found suggesting the existence of transcripts containing exons 2 and 3. All of the cDNA sequences that were resolved matched the consensus and subject sequences.

The candidacy of *POU2F1* as the antecedent mutation of *DFNA7* is weakened. However, rejection at this stage is precluded by methodical shortcomings and uncertainty about the existence of additional exons.

Introduction

Incidence of hearing loss

Hearing impairment (HI) is a common affliction. In developed countries prelingual HI affects about 1 in 1000 children^{1,6}. An additional 1 in 1000 children develop a post lingual hearing deficit. Incidence of HI increases with increasing age. A handicapping loss of hearing is manifested in 3 in 1000 individuals between the ages of 30 and 50 years, rising to 23 in 1000 of those between 60 and 70 years. An estimated 50 % of octogenarians have a handicapping loss of hearing^{1,5}.

Genetics of hearing impairment

Genetics plays an important role in congenital HI and doubtlessly also in presbyacusis. About half of all cases of congenital HI are caused by genetic defects². The majority (70%) of these mutations affect only the auditory system (nonsyndromic) making early diagnosis difficult. In the remaining 30% HI is one of a number of clinical features present in affected individuals (syndromic). Nonsyndromic HI is further divided into autosomal dominant (20%) and recessive (80%) types (ADD and ARD), X-linked HI (~1%) and HI linked to loci in mitochondrial DNA (< 1 %).

Syndromic HI is conductive in most cases⁴. ARD is almost always sensorineural and severe. ADD is usually post-lingual and progressive consistent with hearing loss due to accumulation of pathology.

A large number of genes can give rise to non-syndromic HI. To date more than 70 loci have been mapped and 25 nuclear genes identified. Of the identified genes, 16 give rise to ADD³. In addition to being a common aetiology of congenital HI and early onset progressive hearing loss, mutations in genes will no doubt be found to play an important role in presbyacusis.

Non-syndromic autosomal dominant deafness locus number 7 (*DFNA7*)

DFNA7 was discovered in a large Norwegian family where affected individuals exhibit non-syndromic autosomal dominant post lingual progressive high-tone hearing loss. Debut age and progression vary but hearing loss does not set in until after age 4-5 years. In the majority of affected family members hearing loss is greater than 45 dB by age 15 years. However the highest frequencies are affected first and individuals retain acceptable social hearing and normal lingual skills. *DFNA7* is thus a mild form of HI.

DFNA7 was mapped to 1q21-q23 on chromosome 1 by linkage analysis. It is a large locus. Bordered by the microsatellite markers D1S104 at the centromeric end and D1S466 at the telomeric end, it stretches 22 cM in length and contains over 100 genes. No other reports of families with linkage to this region have been published since its discovery and there has been no progress in refining the genetic region. Because of the large size of the region studies have focused on identification and testing of candidate genes, of which there are several^{8,9}. So far myelin protein zero (MPZ or P0), Cx40 and Cx50 have been tested by SSCP analysis and/or sequencing.

POU domain class 2 transcription factor 1; *POU2F1*

POU2F1 (alternatively *OTF-1* and *OCT-1*) is one of several candidate genes located in 1q21-q23. The gene spans ~ 200 kb of the genome and probably contains more than 21 exons^{14,15} though currently confirmed transcripts contain 16 exons or fewer. It encodes a helix-loop-helix transcription factor which is a member of the POU-domain family of proteins. The POU-domain is a structural motif containing two DNA-binding domains, a 75 amino acid POU-specific domain and a 60 amino acid POU-homeodomain separated by a short 20 amino acid spacer. The POU-homeodomain is related to the homeodomains of many other transcription factors. Members of the POU-domain family are important during development of the nervous system¹².

POU2F1 is an attractive candidate gene for *DFNA7* for a few reasons:

1. Similar genes involved in earlier characterised deafness loci with similar clinical manifestations.
2. Close proximity of *POU2F1* to the micro satellite marker D1S196 which gave the highest lod-score.
3. *POU2F1* is expressed in rat cochlea during embryogenesis¹².

Mutant forms of two genes related to *POU2F1*, namely *POU3F4* and *POU4F3* have been shown to cause progressive sensorineural hearing loss. The *POU3F4* gene is involved in X-linked progressive sensorineural HI combined with stapes fixation¹⁰ and *POU4F3* is involved in autosomal dominant progressive sensorineural hearing loss¹¹. The *POU2F1* gene is located on chromosome 1 only 0.8-cM from the D1S196 marker which gave the highest lod-score with *DFNA7*⁸. The *POU2F1* gene has been reported to be expressed in the rat cochlea during embryogenesis, consistent with its contribution to inner ear development⁷.

The protein product of *POU2F1*, OCT-1 is ubiquitously expressed. The fact that OCT-1 is expressed in all eukaryotic cells may seem to undermine its candidacy as a genetic determinant of disease in such specialised tissues as those found in the inner ear. However there are potentially many ways in which a mutation in OCT-1 might lead to disease. OCT-1 may participate in tissue specific transcription via direct protein-protein interactions and protein-protein interactions mediated by the various OCT-1 DNA binding sites. Also, splice variants and tissue specific isoforms of OCT-1 (and mouse homologues) have been characterised^{13,14,15}. The occurrence of a mutation affecting only interactions that take place in the inner ear is a plausible explanation as is mutation within a tissue-specific exon of an alternatively spliced isoform of Oct-1. The inner ear is an immensely complex organ and even slight aberrations of expression at key points during embryogenesis could lead to disease.

Material and methods

Clinical material




Figure 1: The pedigree for the Norwegian deafness family. The 42 family members included in the study carried out by Fagerheim et al⁸ are indicated with a dot and have their corresponding liability class number below their pedigree number. Liability class number I (10-15 years), II (16-20 years), III (21-25 years) and IV (>25 years) have the penetrance values of 0.5, 0.75, 0.90 and 0.99 respectively.

Subjects III:17, III:21, III:18 and III:24 were selected and assigned numbers 1 – 4 respectively. As indicated in figure 1, subjects 1 and 2 exhibited symptoms, whilst subjects 3 and 4 did not.

Acquisition of the consensus sequence and primer design

The consensus sequence, the exon boundaries and the flanking intron sequences of *POU2F1* were obtained by searching the nucleotide databases GenBank at NCBI (<http://www.ncbi.nlm.nih.gov>) and ENSEMBL (<http://www.ensembl.org/>) with the search terms *POU2F1* and OCT-1. “Blast 2 sequences” (<http://www.ncbi.nlm.nih.gov/gorf/bl2.html>) was used to compare exons of the new transcripts with those of the original transcript (see results).

All primers were designed using the web-based primer design program Primer 3 (http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). The same primers were used for both PCR and sequencing reactions.

Exonal and intronal primers.

Two sequencing goals demanded two types of primers. Intronal primers (see table 1 for primer sequences) were required to obtain full length sequences of the individual exons from the genomic DNA of the patients. To ensure optimal resolution of the target exon and flanking intron bases, primers were designed to amplify the target exon and a “buffer region” of at least 40 base pairs either side of the exon.

Exonal primers (table 2) on the other hand were used to sequence *POU2F1* cDNA from a healthy subject in order to corroborate the sequence information available at the databases. After attempts at amplifying entire cDNAs failed, we chose to sequence the cDNA in a series of overlapping fragments. Because of uncertainties concerning the initial exons the first primer set had 5 forward primers. The primer sets are colour coded in table 3.

Before commencing sequencing of the subject DNA, the first batch of intronal primers was tested on genomic DNA isolated from an arbitrary whole blood sample from the blood bank at the University Hospital of Tromsø. Testing of the second batch of primers (for exons 1-3 and 7) and the exon primers was deemed unnecessary because of the good results obtained with the first batch.

Mixing of reagents and thermal cycling parameters were identical to those used in PCR (see tables 4 and 5).

Table 1: Primers used for PCR and sequencing of genomic DNA from subjects. To provide optimal templates for sequencing, primers were designed to amplify the target exon and at least 40 intronal base pairs either side of the exon.

Name	Sequence (5'-3')	Size of PCR prod.
POU2-EX1-F1	AGAGGAGGGAGGAGGCAAG	277
POU2-EX1-R1	CATCTCCCCGCCGTAAAT	
POU2-EX2-F1	GGGCATGACTCAAAGAGGTC	399
POU2-EX2-R1	GCATACCAAATGGGCTTCAT	
POU2-EX3-F1	CCCCCACTGTGTGAATTGTT	250
POU2-EX3-R1	CACCTGGATTTATCAGATGCTAC	
POU2-EX4-F1	TGTGTGATGGGTTTGTGGA	364
POU2-EX4-R1	ACATCCAGCCTGGTCATGTT	
POU2-EX5-F1	TTGCTTTCCCCTTAATCCA	263
POU2-EX5-R1	GCATAGTCAACCCGACACAC	
POU2-EX6-F1	CAGTTTGCCTCCTCAATCC	207
POU2-EX6-R1	GTTACATGGAAACTTCTCTTTGTG	
POU2-EX7-F1	GCAGATGCAATCGGGTTTAT	490
POU2-EX7-R1	TTGACCAGAACATGCTGA	
POU2-EX8-F1	GGTGCCTGATGAATGTTGGT	254
POU2-EX8-R1	TCAGGCCAGTACTTTACG	
POU2-EX9-F1	GGGTAGGGTGGGTTGAGAAG	446
POU2-EX9-R1	TTCCTGTCCATTTGGTTCA	
POU2-EX10-F1	TGATTCCCTAAAAGATGGGGTTT	260
POU2-EX10-R1	CCAATGGCAGTTCTGACACA	
POU2-EX11-F1	AGCAGTGGCTTGCAATTAGG	357
POU2-EX11-R1	AGGCCAACACTAACATCA	
POU2-EX12-F1	CAGAACATCAGCTGGAAGC	307
POU2-EX12-R1	AATAGTTTCAGGGCAAAATGA	
POU2-EX13-F1	TTTCTTTGCCATGTGTTCG	218
POU2-EX13-R1	CCAAAAGTCTCCCCAAACAA	
POU2-EX14-F1	TCCATAAATGTGGCTTTCC	353
POU2-EX14-R1	TGTGGAATCCATGAATACAGAGAG	
POU2-EX15-F1	AGGCTTAAGCACTGGTGAGA	280
POU2-EX15-R1	CCAATTATATAACAATCCCCATGT	
POU2-EX16-F1	CTTGGATGTAGCTATTTGTCAGTT	297
POU2-EX16-R1	TTAAGTACTACACAGACAATCCCATGT	
POU2-EX17-F1	CCTGACGTGATTATGCCAGTAG	308
POU2-EX17-R1	AAATTGCAAAAATTAGCCCTTG	
POU2-EX18-F1	CGAATAGCAGCTTCCAACA	336
POU2-EX18-R1	TTAGTTAGGGCTTAATTACAATT	
POU2-EX19-F1	AAAGCCACCATTCTCCAAA	455
POU2-EX19-R1	GGATGACCTCCACCTCAGAC	
POU2-EX20-F1	AAAATGAGACCTGCGTCTGC	230
POU2-EX20-R1	TCTGTCTCAAGCACACACACA	
POU2-EX21-F1	CCTGGTGGGTTGTAGGAAAA	479
POU2-EX21-R1	GCTGGCAGTCCAATCACAC	

Table 2: Primers for amplification and sequencing of *POU2F1* cDNA.

Name	Sequence (5'-3')
IE-EX1-F1	GAGGAGCAGCGAGTCAGAT
IE-EX2-F1	CAGTGATGCCAGCAAAATGT
IE-EX3-F1	AGAAGAGCTTCCTGCCTTTT
IE-EX3-R1	GAUTGCATTCTTCTTGAUTG
IE-EX4-F1	GGTTGGAAAGGATAATTGGGTGACT
IE-EX5-F1	CCACCCCCAAACTGCTACCT
IE-EX6-F1	CCGTCAGAACCCAGTAAACCA
IE-EX6-R1	TTGCCATCTCCACTCTCCAT
IE-EX11-F1	ACTACTCCAGCAGGCACAGG
IE-EX11-R1	GCGATCTGTATGGGTGAGA
IE-EX16-F1	TCTGATTCTGTCCCCTCTCCAG
IE-EX16-R1	CTCTAAGGCCACACGGATGT
IE-EX19-F1	CACCACCTCCAACAACACAG
IE-EX19-R1	CAGGCTTGGGTTAGTCCTG
IE-EX21-R1	CGAGAGGAAGCCAATCACAT

Table 3: Location and orientation of the exon primers for cDNA sequencing with expected product sizes and resulting fragments. Primer sets and fragments are colour coded. Sequences of primers are presented in table 2.

Exon	E-primers	Prod. size*	Resulting fragments
1	↓ ↓ **	140/112	
2	↓	247	***
3	↑ ↓	150	*** A
4	↓	154	***
5	↓	156	***
6	↓ ↑	509	
7			
8			B
9			
10			
11	↑ ↓	823	
12			
13			C
14			
15			
16	↓ ↑	735	
17			D
18			
19	↑ ↓	836	
20			E
21	↑		

*Product sizes are affixed to the adjacent forward primer and denote the length in base pairs between the forward and reverse primers. Absence of intervening exons was assumed during calculation for the first 5 forward primers. These figures represent therefore minimum product size.

**The two arrows here represent one forward primer which is compatible with two reverse primers.

***Intervening exons did not appear in cDNA fragment A.

Template acquisition

Isolation of genomic DNA

DNA was extracted from EDTA blood using the standard protocol for the Applied Biosystems GENEPURE 341 Nucleic Acid Purification System.

Synthesis of cDNA

RNA from a healthy donor was isolated from whole blood using the PAXgene Blood RNA System from PreAnalytiX and cDNA was synthesised using the SuperScript™ First-Strand Synthesis System for RT-PCR from Invitrogen. The manufacturer's protocols were followed without deviation. Briefly outlined, stabilised mRNA was reverse transcribed using the retrovirus protein reverse transcriptase. Oligo dT primers targeting the poly A tails of the mRNA served as starting points for reverse transcription. The RNA template was subsequently digested with RNase leaving single stranded cDNA ready for PCR.

Automatic sequencing

PCR

Prior to sequencing the target DNA was amplified by polymerase chain reaction (PCR). A touchdown-PCR protocol (touchdown refers to diminishing annealing temperature) was used in order to circumvent non-specific priming, thereby increasing the efficiency of PCR. Reagents were mixed in polypropylene PCR tubes as indicated in table 4 and subsequently thermally cycled in a MBS 0.2G/S thermocycler from Hybaid. The cycling parameters are shown in table 5.

Table 4: Mixing of reagents for PCR.

Reagent	Concentration	Pr. reaction
Primer F	20 Pmol/ μ l	0.25 μ l
Primer R	20 Pmol/ μ l	0.25 μ l
RedTaq* PCR mix.	2.5 U/ μ l	7.5 μ l
Template	5 ng/ μ l	2 μ l
Water		6 μ l
Total		15 μ l

* From Sigma

Table 5: Cycling parameters for PCR. Extension times were lengthened to 50 seconds during amplification of cDNA fragments.

Phase	Cycles	Temp. (°C)	Time
Initial denature	1	94	8 min
Denature		95	20 sec
Anneal	2	63	20 sec
Extend		72	20 sec
Denature		95	20 sec
Anneal	2	61	20 sec
Extend		72	20 sec
Denature		95	20 sec
Anneal	2	59	20 sec
Extend		72	20 sec
Denature		95	20 sec
Anneal	30	57	20 sec
Extend		72	20 sec
Cool	1	4	∞

Electrophoresis

To ensure that PCR produced the desired product, samples were run on agarose gels with a DNA size marker. The band pattern produced was correlated with the expected product sizes (see tables 1 and 3 and figures 4-6).

A suitably sized plastic casting mould and well comb were selected and levelled. Two hundred ml 1 X TBE buffer was added to 2.0 g agarose in a flask. The mixture was brought to boil in a microwave oven and then cooled to ~ 55°C. The gel mixture was then poured into the casting mould so that the depth of the liquid was ~ 5-6 mm. The gel was left to polymerise at room temperature for 20 minutes and the remaining gel mixture was stored at 55°C for later use. The stiffened gel was placed in an electrophoresis chamber containing 1 x TBE buffer with the wells positioned adjacent to the negative electrode (DNA migrates towards the positive electrode). The level of the electrophoresis buffer was adjusted so that the gel was covered. DNA samples (already containing RedTaq loading buffer) were applied to the wells along with the DNA size marker (1 kb plus, figure 2). The electrophoresis was run at 90 V for ~45 minutes. Following electrophoresis the gel was soaked in ethidium bromide solution (10 mg/ml). Bands were visualised and photographed using a Dual Intensity Transilluminator (ULTRAVIOLET PRODUCTS) UVP Imagestore 5000 (SONY). (UV light at 302 nm).




Figure 2: Ready-Load™ “1 Kb Plus” DNA ladder.

Cleaning the PCR product

In order to remove primers and inactivate (dephosphorylate) residual free nucleotides, which would otherwise disturb the sequencing reaction, the PCR product was treated with the two enzymes exonuclease I and shrimp alkaline phosphatase (EXO-SAP). To the PCR product, of which ~10 µl remained, 1 µl of a pool containing 1 U SAP and 5 U EXO/µl was added. The reaction was then incubated at 37°C for 1 hour and subsequently deactivated at 85°C for 15 minutes.

Sequencing

The reagents were mixed as shown in table 6 and the tubes were subjected to temperature cycling as shown in table 7.

Table 6: Mixing of reagents for sequencing PCR

Component	Concentration	Volume (µl)
DNA template (PCR product)	~50 ng/µl	3
Big Dye™ terminator RR mix*	10 ×	2
Big Dye™ sequencing buffer*	6.67 ×	3
Primer (either 3' or 5')	3 pmol/µl	1
MilliQ water		11
Total		20

*PE Applied Biosystems

Table 7: Cycling parameters for sequencing PCR

Phase	No. cycles	Temperature (°C)	Time
Denature		95	30 sec
Anneal	30	50	5 sec
Extend		60	4 min
Cool	1	4	∞

Precipitation of the sequencing product

The automatic sequencing team at UiTø requires that the sequencing product be precipitated and dried before delivery.

The sequencing PCR product (20 µl) was added to a mixture of 2 µl 3M sodium acetate (pH 4.6) and 50 µl 96 % ethanol in a micro-centrifuge tube. The mixture was incubated at room temperature for 20 minutes and then centrifuged for 15 minutes at 13000 rpm in a Biofuge 13 (HERAEUS, SEPATECH). The supernatant was removed by suction and the pellet washed with 250 µl 70% ethanol, vortexing briefly. The purified DNA was then centrifuged at 13000 rpm for 5 minutes, again removing the supernatant by suction. Lastly the pellet was air dried for 20 minutes and stored at -20°C prior to automatic sequencing.

Sequencing electrophoresis

The sequencing reaction products were run on an ABI 377 Automatic DNA sequencer.

Sequence analysis

Sequencing 21 exons from 4 patients in both directions generated a large amount of data. The sequence data was analysed using the programs Sequence Analysis 3.7 and Seqscape. A consensus sequence consisting of 21 exons was created with which the sequence information from the cDNA donor and the 4 patients was aligned. The alignments were studied both automatically and manually, comparing with the chromatogram alignments when necessary.

Results and discussion

Acquisition of the consensus sequence and primer design

Searches of the database at ENSEMBL at two different stages (2 months apart) gave differing results. Initially a gene with a single transcript was obtained. Upon searching a second time the gene had 4 transcripts which contained 4 additional exons while 2 were omitted. We chose to include all of the exons found in both searches in the study. The 21 exons with ENSEMBL IDs and sizes are presented in table 8.

The reason for the differing search results lies in the nature of the ENSEMBL system and unfinished human genome project. ENSEMBL is an automated system for tracking, assembling and analysing sequenced fragments of the human genome (as well as other species). The database is constantly evolving due to the ever increasing flood of new sequence fragments and activity was intense in the months leading up to April 2003 at which point 99 % of the human genome project was expected to be finished.

Table 8: Comparison of the 5 ENSEMBL transcripts of pou2f1. Exons are numbered 1-21 in order of occurrence in genomic DNA. Initial 9 characters of the ENSEMBL exon IDs (ENSE00000) are omitted to save space. Sets of exons with matching DNA sequences are aligned along the same row (note that one exon may have more than one ID). Exons with no matching counterparts are highlighted in blue.

No.	Orig. ENST-00000308928	ENST00000-271411	ENST00000-308928	ENST00000-308943	ENST00000-318156	Exon size (bp)
1		1218788	1200261	1218961	1200261	51/61/64
2			1218885		1218794	205/204
3				1200259		101
4	1200252					98
5	1200238					137
6	0958560	1218925	0958560		1218925	66/67
7			1218948			290
8	0958561	0958561	0958561		0958561	101
9	0958562	0958562	0958562		0958562	54
10	0958563	0958563	0958563		0958563	120
11	0958564	0958564	0958564		0958564	189
12	0958565	0958565	0958565		0958565	127
13	0958566	0958566	0958566		0958566	95
14	1200208	0958567	0958567		0958567	174
15	1200205	0958568	0958568		0958568	142
16	1200204	0958569	0958569		0958569	140
17	1200201	0958570	0958570		0958570	180
18	1200248	1157574	1157574		1157574	106
19	1157566	1157566	1157566		1157566	346
20	0958573	0958573	0958573		0958573	89
21	1218941	0958574*	1218941		1218941	387/604

*0958574 is the same as 1218941 but includes a 3' untranslated region.

Testing of primers

The first batch of intronal primers (for exons 4-6 and 8-21) gave good results immediately without need for optimisation (see figure 3).




Figure 3: Results of primer testing for intronal primer sets for exons 4-6 and 8-21. The expected product sizes are presented in table 1. Template DNA is genomic DNA isolated from an arbitrary whole blood sample from blood bank at the University Hospital of Northern Norway. Mixing of reagents and thermal cycling parameters were identical to those used in pre-sequencing PCR (see tables 4 and 5). Primer sets for exons 1-3 and 7 were not tested prior to use.

Automatic sequencing

PCR

Subject DNA

All of the intronal primer sets gave visible bands of varying intensity in the vicinity of the expected product sizes though some gave extra bands (see figures 4 and 5).




Figure 4: Results of PCR for exons 1-8. The expected product sizes are presented in table 1. Template DNA is genomic DNA isolated from subjects 1-4, here denoted as patient (P) 1-4. Mixing of reagents and thermal cycling parameters are presented in tables 4 and 5.




Figure 5: Results of PCR for exons 9-21. The expected product sizes are presented in table 1. Template DNA is genomic DNA isolated from subjects 1-4, here denoted as patient (P) 1-4. Mixing of reagents and thermal cycling parameters are presented in tables 4 and 5.

cDNA

Because the cDNA was in short supply the 4 forward primers IE-EX2-F1, IE-EX3-F1, IE-EX4-F1, IE-EX5-F1 and the reverse primer IE-EX3-R1 (see table 2 and 3) were not used in PCR. Instead the first forward primer in the set (IE-EX1-F1) was used in the hope that it would amplify all the intervening exons. In tune with a well known set of natural laws, the polymerase chain reaction favoured the amplification of the shortest possible sequence. However, a smear of ghost bands trailed the main product (see figures 6; A and 7) spiking the curiosity and providing an opportunity to use the 4 afore mentioned forward primers. Thus, 1:10 and 1:100 dilutions of fragment A were used as template in nested PCR in an attempt to establish the identity of the extra exons in the ghost bands. The results are illustrated in figure 8.




Figure 6: Results of PCR for overlapping cDNA fragments A-E. The expected product sizes are presented in table 3. Primer sets were as follows A = IE-EX1-F1 + IE-EX6-R1, B = IE-EX6-F1 + IE-EX11-R1 C = IE-EX11-F1 + IE-EX16-R1 D = IE-EX16-F1 + IE-EX19-R1, E = IE-EX19-F1 + IE-EX21-R1. Template DNA was cDNA isolated from a normal subject. Mixing of reagents and thermal cycling parameters are presented in tables 4 and 5 (note that extension time was 50 seconds).



Figure 7: Duplicate of fragment A in figure r4 adjusted to bring out the extra bands.




Figure 8: Nested PCR on EXO-treated fragment A (see figure 6 and 7) diluted 1:10 and 1:100. All reactions contained the reverse primer IE-EX6-R1. Reactions 1 and 5 contained the forward primer IE-EX2-F1, while reactions 2 and 6 contained IE-EX3-F1, reactions 3 and 7 contained IE-EX4-F1 and finally reactions 4 and 8 contained IE-EX5-F1. Mixing of reagents and thermal cycling parameters were identical to those used in pre-sequencing PCR.

The presence of a band in well 1 (see figure 8) indicates that at least part of the new ENST0000308928 transcript (see table 8) is present in blood. Presence of a band in well 2 is more surprising and suggests that a novel transcript including exons 3 (ENSE00001200259) and 6 (ENSE00001218925/0958560) is also present in blood. This may however simply be a reflection of the tendency towards long non-specific transcripts in blood. There was no evidence supporting co-occurrence of exon 1 with exons 4 and 5 in transcripts.

Sequencing

Subject DNA

Sequencing from the genomic DNA of the 4 subjects went more or less smoothly and full length sequences for all the exons were attained (see alignments in appendix). Although there were many aberrations in the form of non-discriminate (N) bases, gaps, inserts and substitutions, all were cancelled by the complementary strand or, failing that, by a new copy of the same strand. There were no obvious differences between the 4 subjects. There were, however uncancelled differences between the subject sequences and the consensus sequence at two sites. The first was a G>C substitution at position 143 in exon 2 (ENSE000001218885). All 4 subject sequences carried the substitution, implying a polymorphism. Unfortunately there is no cDNA sequence of exon 2 to substantiate the implication. The second, almost unworthy of mention, was a G>A/N substitution in the 8th base of the 3' flanking intron sequence of exon 20 (mutations in bases immediately adjacent to exons can give rise to problems during mRNA splicing). Only forward sequences appeared to be disturbed (see figure accompanying exon 20 in appendix), which suggests that it was simply an artefact of sequencing. The substitution is mentioned here because it remained uncancelled in subjects 2 and 3. All attempts at reverse sequencing exon 20 of subjects 2 and 3 resulted in unreadable double sequences. The sequences were displaced 4 positions over the entire length indicating mispriming perhaps as a result of a mutation the primer binding site in the intron but more likely because of a sub-optimal primer sequence (see figure accompanying exon 20 in appendix).

cDNA

Sequencing Pou2f1 cDNA was less successful and exons 2-5 and 7 were not covered. The 5' end of exon 1 was not resolved and there were several uncancelled Ns as well as a G>C substitution near the 3' end of exon 21. However the substitution and all but two of the Ns could be attributed to artefacts of sequencing (see figures accompanying exons 16 and 21 in appendix).

Conclusion

No mutations were found in the 21 exons studied. This makes *POU2F1* a less likely candidate for *DFNA7*. However, *POU2F1*'s candidacy cannot be rejected unequivocally at this point for several reasons.

Firstly, apart from the ubiquitously expressed OCT-1 protein, two tissue specific isoforms of human OCT-1 have been discovered in lymphocytes^{13,14} and several murine isoforms have been reported¹⁵. Given the high level of evolutionary conservation between these two species, there may well be several human isoforms of OCT-1 yet to be discovered. Perhaps a cochlea specific isoform with 1 or more unique exons exists. The fact that the sequence information regarding the original *POU2F1* gene transcript was removed and 4 new transcripts were added to the ENSEMBL database during the course of this study illustrates the incomplete understanding of the array of expression products.

Secondly, *DFNA7* exhibits autosomal dominant inheritance, meaning that only one chromosome is affected. We cannot be certain that the sequences produced in this study represent both chromosomes. Theoretically the mutation itself could cause sequencing of the affected chromosome to fail so that only the normal sequence is resolved. For example, a large insertion could increase the length of the mutated exon so that the shorter, non-mutated exon is preferentially amplified during PCR. This is particularly relevant for the newly discovered exons which have not yet been tested for large rearrangements by southern blot or SSCP.

Thirdly, mutations affecting the *POU2F1* gene need not lie within the gene itself. A mutation in an enhancer or promoter (control) region could cause reduced expression. Such mutations are more challenging to associate to disease and in the case of *POU2F1* no control regions are as yet defined.

In an incidental finding, a novel transcript including exons 3 (ENSE00001200259) and 6 (ENSE00001218925/0958560) (compare with table 8) appeared to be present in blood. This finding may simply be a reflection of the tendency towards long non-specific transcripts in blood or it may indicate the existence of a novel isoform of OCT-1.

In order to rule out mutation in *POU2F1* as the antecedent of *DFNA7*, future studies could include mutational analysis (by SSCP and sequencing) of all new exons and control regions as the consensus data is presented at ENSEMBL. Screening for expression of OCT-1 and its possible isoforms in cDNA libraries from human cochlea at different stages of development, may also be helpful.

References


1. Morton NE. Genetic epidemiology of hearing impairment. *Ann N Y Acad Sci.* 1991;630:16-31.
2. Marazita ML, Ploughman LM, Rawlings B, Remington E, Arnos KS, Nance WE. Genetic epidemiological studies of early-onset deafness in the U.S. school-age population. *Am J Med Genet.* 1993 Jun 15;46(5):486-91.
3. Petersen MB. Non-syndromic autosomal-dominant deafness. *Clin Genet.* 2002 Jul;62(1):1-13.
4. Petit C. Genes responsible for human hereditary deafness: symphony of a thousand. *Nat Genet.* 1996 Dec;14(4):385-91.
5. Nadol JB Jr. Hearing loss. *N Engl J Med.* 1993 Oct 7;329(15):1092-102.
6. Anderssen SH, Andresen J, Andersen R, Sponheim L. [Universal neonatal hearing screening of infants with otoacoustic emissions]. *Tidsskr Nor Laegeforen.* 2002 Sep 20;122(22):2187-9.
7. Ryan AF, Crenshaw EB III, Simmons DM. Gene expression in normal and abnormal inner ears. *Ann N Y Acad Sci.* 1991;630:129-32.
8. Fagerheim T, Nilssen O, Raeymaekers P, Brox V, Moum T, Elverland HH, Teig E, Omland HH, Fostad GK, Tranebjaerg L. Identification of a new locus for autosomal dominant non-syndromic hearing impairment (DFNA7) in a large Norwegian family. *Hum Mol Genet.* 1996 Aug;5(8):1187-91.
9. Tranebjaerg L, Elverland HH, Fagerheim T. DFNA7. *Adv Otorhinolaryngol.* 2000;56:97-100.
10. de Kok YJ, van der Maarel SM, Bitner-Glindzicz M, Huber I, Monaco AP, Malcolm S, Pembrey ME, Ropers HH, Cremers FP. Association between X-linked mixed deafness and mutations in the POU domain gene POU3F4. *Science.* 1995 Feb 3;267(5198):685-8
11. Vahava O, Morell R, Lynch ED, Weiss S, Kagan ME, Ahituv N, Morrow JE, Lee MK, Skvorak AB, Morton CC, Blumenfeld A, Frydman M, Friedman TB, King MC, Avraham KB. Mutation in transcription factor POU4F3 associated with inherited progressive hearing loss in humans. *Science.* 1998 Mar 20;279(5358):1950-4.
12. He X, Treacy MN, Simmons DM, Ingraham HA, Swanson LW, Rosenfeld MG. Expression of a large family of POU-domain regulatory genes in mammalian brain development. *Nature.* 1989 Jul 6;340(6228):35-41. Erratum in: *Nature* 1989 Aug 24;340(6235):662.
13. Pankratova EV, Deyev IE, Zhenilo SV, Polanovsky OL. Tissue-specific isoforms of the ubiquitous transcription factor Oct-1. *Mol Genet Genomics.* 2001 Oct;266(2):239-45.
14. Luchina NN, Krivega IV, Pankratova EV. Human Oct-1L isoform has tissue-specific expression pattern similar to Oct-2. *Immunol Lett.* 2003 Feb 3;85(3):237-41.
15. Riss J, Laskov R. Expression of novel alternatively spliced isoforms of the oct-1 transcription factor. *Biochim Biophys Acta.* 1999 Feb 16;1444(2):295-8.

Appendix

Note: "P1, P2, P3 and P4" refer to subjects 1-4. "c-A, c-B, c-C, c-D and c-E" denote cDNA fragments A-E (see table 3). -F = forward sequence and -R = reverse sequence.

Exon 1 (ense 00001200261)

P1-F 141	-----	-----	-----	TAT	TTGGGCGCNA	GGGGGGAGGG	GAGCCNGAGC	GAGGGAGGGT
P1-R 142	-GNNNNNNNNN	NNNNNNNNNT	TAGAGGAGGG	AGGAGGCAG	CAGGGCGGG	GGGGGGAGGG	GAGCCAGAGC	GAGGGAGGGT
P2-F 143	-----	-----	-----	-CGGGGA	GGGGGGAGGG	GAGCNAGAGC	GAGGGAGGGT	
P2-R 144	GNNNNNNNNN	NNNNNNNNNT	TAGAGGAGGG	AGGAGGCAG	CAGGGCGGG	GGGGGGAGGG	GAGCCAGAGC	GAGGGAGGGT
P3-F 145	-----	-----	-----	-CGGGGA	GGGGGGAGGG	GAGCNAGAGC	GAGGGAGGGT	
P3-R 146	-----	NNNTT	TAGAGGAGGG	AGGAGGCAG	CAGGGCGGG	GGGGGGAGGG	GAGCCAGAGC	GAGGGAGGGT
P4-F 147	-----	-----	-----	-CGGGNA	GGGGGGAGGG	GAGCNAGAGC	GAGGGAGGGT	
P4-R 148	-GNNNNNNNNN	NNNNNNNNNT	TAGAGGAGGG	AGGAGGCAG	CAGGGCGGG	GGGGGGAGGG	GAGCCAGAGC	GAGGGAGGGT
	10	20	30	40	50	60	70	80
REF	taaaaat	tcAAATGGC	GGACGGAGGA	GCAGCGAGTC	A-AGATGAGA	GTTCAGCCGC		
c-A-F 173							-GAGN	GTTCAGCCGC
c-A-R 174		NNCNCNC	CCNTTGAGGA	GCAGCGAGTC	A-AGATGAGA	GTTCAGCCGC		
P1-F 141	TTATCGACCG	GGCGATTTTG	GTTAAAATAT	TCAAAATGGC	GGACGGAGGA	GCAGCGAGTC	A-NGATGAGA	GTTCAGCCGC
P1-R 142	TTATCGACCG	GGCGATTTTG	GTTAAAATAT	TCAAAATGGC	GGACGGAGGA	GCAGCGAGTC	A-AGATGAGA	GTTCAGCCGC
P2-F 143	TTATCGACCG	GGCGATTTTG	GTTAAAATAT	TCAAAATGGC	GGACGGAGGA	GCAGCGAGTC	A-AGATGAGA	GTTCAGCCGC
P2-R 144	TTATCGACCG	GGCGATTTTG	GTTAAAATAT	TCAAAATGGC	GGACGGAGGA	GCAGCGAGTC	A-AGATGAGA	GTTCAGCCGC
P3-F 145	TTATCGACCG	GGCGATTTTG	GTTAAAATAT	TCAAAATGGC	GGACGGAGGA	GCAGCGAGTC	A-AGATGAGA	GTTCAGCCGC
P3-R 146	TTATCGACCG	GGCGATTTTG	GTTAAAATAT	TCAAAATGGC	GGACGGAGGA	GCAGCGAGTC	A-AGATGAGA	GTTCAGCCGC
P4-F 147	TTATCGACCG	GGCGATTTTG	GTTAAAATAT	TCAAAATGGC	GGACGGAGGA	GCAGCGAGTC	A-AGATGAGA	GTTCAGCCGC
P4-R 148	TTATCGACCG	GGCGATTTTG	GTTAAAATAT	TCAAAATGGC	GGACGGAGGA	GCAGCGAGTC	A-AGATGAGA	GTTCAGCCGC
	90	100	110	120	130	140	150	160
REF	GGCGGCAGCA	GCAGCAGGta	atcattta					
c-A-F 173	GGCGGCAGCA	GCAGCAG						
c-A-R 174	GGCGGCAGCA	GCAGCAG						
P1-F 141	GGCGGCAGCA	GCAGCAGGTA	ATCAATTACAG	CATTTTACAT	ATTCAATTTC	ATACTCAACC	CCGGCTCCCC	CTGCCCCCC
P1-R 142	GGCGGCAGCA	GCAGCAGGTA	ATCAATTACAG	CATTTTACAT	ATTCAATTTC	ATACTCAACC	CCGGCTCCCC	CTGCCCCCC
P2-F 143	GGCGGCAGCA	GCAGCAGGTA	ATCAATTACAG	CATTTTACAT	ATTCAATTTC	ATACTCAACC	CCGGCTCCCC	CTGCCCCCC
P2-R 144	GGCGGCAGCA	GCAGCAGGTA	ATCAATTACAG	CATTTTACAT	ATTCAATTTC	ATACTCAACC	CCGGCTCCCC	CTGCCCCCC
P3-F 145	GGCGGCAGCA	GCAGCAGGTA	ATCAATTACAG	CATTTTACAT	ATTCAATTTC	ATACTCAACC	CCGGCTCCCC	CTGCCCCCC
P3-R 146	GGCGGCAGCA	GCAGCAGGTA	ATCAATTACAG	CATTTTACAT	ATTCAATTTC	ATACTCAACC	CCGGCTCCCC	CTGCCCCCC
P4-F 147	GGCGGCAGCA	GCAGCAGGTA	ATCAATTACAG	CATTTTACAT	ATTCAATTTC	ATACTCAACC	CCGGCTCCCC	CTGCCCCCC
P4-R 148	GGCGGCAGCA	GCAGCAGGTA	ATCAATTACAG	CATTTTACAT	ATTCAATTTC	ATACTCAACC	CCGGCTCCCC	CTGCCCCCC
	170	180	190	200	210	220	230	240
P1-F 141	CCCGGACTTA	GCATAATTAA	TTAGTACTCA	GGATTATTAT	A'TTAACGGC	GGGGAGANGN	NAANNNNNNN	TNNNNNNNN
P1-R 142	CCCGGACTTA	GCATAATTAA	TTAGTACTCA	NNATGNGNNC	AAA			
P2-F 143	CCCGGACTTA	GCATAATTAA	TTAGTACTCA	GGATTATTAT	A'TTAACGGC	GGGGAGANGN	AAANNNNNNN	NNNNNNNN
P2-R 144	CCCGGACTTA	GCATAATTAA	TTAGTACTCA	NNANGNNNC	ANNA			
P3-F 145	CCCGGACTTA	GCATAATTAA	TTAGTACTCA	GGATTATTAT	A'TTAACGGC	GGGGAGANGN	NAANNNNNNN	NNNNNNNN
P3-R 146	CCCGGACTTA	GCATAATTAA	TTAGTACTCA	ATGNGNCA	--			
P4-F 147	CCCGGACTTA	GCATAATTAA	TTAGTACTCA	GGATTATTAT	A'TTAACGGC	GGGGAGANGG	NAANNNNNNN	NNNNNNNN
P4-R 148	CCCGGACTTA	GCATAATTAA	TTAGTACNC	--				
	250	260	270	280	290	300	310	320
P1-F 141	C 283							
P1-R 142	- 281							
P2-F 143	C 276							
P2-R 144	- 283							
P3-F 145	N 276							
P3-R 146	- 261							
P4-F 147	C 276							
P4-R 148	- 267							



Exon 2 (ense 00001218885)

P1-F 149	-----	-----	-----	-----	TNAT	GNAGAATCTG	TTTTTTAGTG	CCGGGTGAAA	TAAC TAAATA
P1-R 150	--NNNNNNNN	NNNNNTTTTG	CGNCC-GCTC	AAAGAGGTCT	GTAGAATCTG	TTTTTTAGTG	CCGGGTGAAA	TAAC TAAATA	
P2-F 151	-----	-----	-----	-----	-GNGAATCTG	TTTTTTAGTG	CCGGGTGAAA	TAAC TAAATA	
P2-R 152	--NNNNNNNN	NNNNNTTTG	GNGCC-GCTC	AAAGAGGTCT	GTAGAATCTG	TTTTTTAGTG	CCGGGTGAAA	TAAC TAAATA	
P3-F 153	-----	-----	-----	-----	TGAGAATCTG	TTTTTTAGTG	CCGGGTGAAA	TAAC TAAATA	
P3-R 154	NNNNNNNNNN	NNNNNTTTG	CNGC-GCTC	AAAGAGGTCT	GTAGAATCTG	TTTTTTAGTG	CCGGGTGAAA	TAAC TAAATA	
P4-F 155	-----	-----	-----	-----	TGAGAATCTG	TTTTTTAGTG	CCGGGTGAAA	TAAC TAAATA	
P4-R 156	-NNNNNNNN	NNNNNTTTG	NGNCCANCTC	AAAGAGGTCT	GTAGAATCTG	TTTTTTAGTG	CCGGGTGAAA	TAAC TAAATA	
	10	20	30	40	50	60	70	80	
				tat	gattctaGCT	ACTACTGGGC	TGTAAACAGT	GATGCCAGCA	
P1-F 149	TTTCGTTTTA	AAAAGGAAGGA	ATTAAATCAGG	AAACCTTTAT	GATTCTAGCT	ACTACTGGGC	TGTAAACAGT	GATGCCAGCA	
P1-R 150	TTTCGTTTTA	AAAAGGAAGGA	ATTAAATCAGG	AAACCTTTAT	GATTCTAGCT	ACTACTGGGC	TGTAAACAGT	GATGCCAGCA	
P2-F 151	TTTCGTTTTA	AAAAGGAAGGA	ATTAAATCAGG	AAACCTTTAT	GATTCTAGCT	ACTACTGGGC	TGTAAACAGT	GATGCCAGCA	
P2-R 152	TTTCGTTTTA	AAAAGGAAGGA	ATTAAATCAGG	AAACCTTTAT	GATTCTAGCT	ACTACTGGGC	TGTAAACAGT	GATGCCAGCA	
P3-F 153	TTTCGTTTTA	AAAAGGAAGGA	ATTAAATCAGG	AAACCTTTAT	GATTCTAGCT	ACTACTGGGC	TGTAAACAGT	GATGCCAGCA	
P3-R 154	TTTCGTTTTA	AAAAGGAAGGA	ATTAAATCAGG	AAACCTTTAT	GATTCTAGCT	ACTACTGGGC	TGTAAACAGT	GATGCCAGCA	
P4-F 155	TTTCGTTTTA	AAAAGGAAGGA	ATTAAATCAGG	AAACCTTTAT	GATTCTAGCT	ACTACTGGGC	TGTAAACAGT	GATGCCAGCA	
P4-R 156	TTTCGTTTTA	AAAAGGAAGGA	ATTAAATCAGG	AAACCTTTAT	GATTCTAGCT	ACTACTGGGC	TGTAAACAGT	GATGCCAGCA	
	90	100	110	120	130	140	150	160	
P1-F 149	AAATGTTACT	TCAGCTGATG	AAAGTGATGCT	GTTTCGAGAA	TTTGAAGCA	ATTTTCAGT	GGATAAAGAA	GTTGACAGCA	
P1-R 150	AAATGTTACT	TCAGCTGATG	AAAGTGATGCT	GTTTCGAGAA	TTTGAAGCA	ATTTTCAGT	GGATAAAGAA	GTTGACAGCA	
P2-F 151	AAATGTTACT	TCAGCTGATG	AAAGTGATGCT	GTTTCGAGAA	TTTGAAGCA	ATTTTCAGT	GGATAAAGAA	GTTGACAGCA	
P2-R 152	AAATGTTACT	TCAGCTGATG	AAAGTGATGCT	GTTTCGAGAA	TTTGAAGCA	ATTTTCAGT	GGATAAAGAA	GTTGACAGCA	
P3-F 153	AAATGTTACT	TCAGCTGATG	AAAGTGATGCT	GTTTCGAGAA	TTTGAAGCA	ATTTTCAGT	GGATAAAGAA	GTTGACAGCA	
P3-R 154	AAATGTTACT	TCAGCTGATG	AAAGTGATGCT	GTTTCGAGAA	TTTGAAGCA	ATTTTCAGT	GGATAAAGAA	GTTGACAGCA	
P4-F 155	AAATGTTACT	TCAGCTGATG	AAAGTGATGCT	GTTTCGAGAA	TTTGAAGCA	ATTTTCAGT	GGATAAAGAA	GTTGACAGCA	
P4-R 156	AAATGTTACT	TCAGCTGATG	AAAGTGATGCT	GTTTCGAGAA	TTTGAAGCA	ATTTTCAGT	GGATAAAGAA	GTTGACAGCA	
	170	180	190	200	210	220	230	240	
P1-F 149	CGATTTGTTG	GATGTGATGA	AGGATTAAATC	AGCATACACC	TTCACTTGT	TTAGCTTAAG	ATGGAATGGT	TCTGGCAAT	
P1-R 150	CGATTTGTTG	GATGTGATGA	AGGATTAAATC	AGCATACACC	TTCACTTGT	TTAGCTTAAG	ATGGAATGGT	TCTGGCAAT	
P2-F 151	CGATTTGTTG	GATGTGATGA	AGGATTAAATC	AGCATACACC	TTCACTTGT	TTAGCTTAAG	ATGGAATGGT	TCTGGCAAT	
P2-R 152	CGATTTGTTG	GATGTGATGA	AGGATTAAATC	AGCATACACC	TTCACTTGT	TTAGCTTAAG	ATGGAATGGT	TCTGGCAAT	
P3-F 153	CGATTTGTTG	GATGTGATGA	AGGATTAAATC	AGCATACACC	TTCACTTGT	TTAGCTTAAG	ATGGAATGGT	TCTGGCAAT	
P3-R 154	CGATTTGTTG	GATGTGATGA	AGGATTAAATC	AGCATACACC	TTCACTTGT	TTAGCTTAAG	ATGGAATGGT	TCTGGCAAT	
P4-F 155	CGATTTGTTG	GATGTGATGA	AGGATTAAATC	AGCATACACC	TTCACTTGT	TTAGCTTAAG	ATGGAATGGT	TCTGGCAAT	
P4-R 156	CGATTTGTTG	GATGTGATGA	AGGATTAAATC	AGCATACACC	TTCACTTGT	TTAGCTTAAG	ATGGAATGGT	TCTGGCAAT	
	250	260	270	280	290	300	310	320	
P1-F 149	ATAAAAATAAC	AGGTTTTCCA	gt						
P1-R 150	ATAAAAATAAC	AGGTTTTCCA	GTTTATTTTT	ATTAC-TGTA	CTTGCTTGT	TATAATATTA	GGCATATTAA	TTAACACCTA	
P2-F 151	ATAAAAATAAC	AGGTTTTCCA	GTTTATTTTT	ATTAC-TGTA	CTTGCTTGT	TATAATATTA	GGCATATTAA	TTNCNNNNNC	
P2-R 152	ATAAAAATAAC	AGGTTTTCCA	GTTTATTTTT	ATTAC-TGTA	CTTGCTTGT	TATAATATTA	GGCATATTAA	TTAACACCTA	
P3-F 153	ATAAAAATAAC	AGGTTTTCCA	GTTTATTTTT	ATTAC-TGTA	CTTGCTTGT	TATAATATTA	GGCATATTAA	TTAACACCTA	
P3-R 154	ATAAAAATAAC	AGGTTTTCCA	GTTTATTTTT	ATTAC-TGTA	CTTGCTTGT	TATAATATTA	GGCATATTAA	NTNC-----	
P4-F 155	ATAAAAATAAC	AGGTTTTCCA	GTTTATTTTT	ATTAC-TGTA	CTTGCTTGT	TATAATATTA	GGCATATTAA	TTAACACCTA	
P4-R 156	ATAAAAATAAC	AGGTTTTCCA	GTTTATTTTT	ATTAC-TGTA	CTTGCTTGT	TATAATATTA	GGCATATTAA	NAAC-----	
	330	340	350	360	370	380	390	400	
P1-F 149	TGAAGCCCAT	TTGANTGCCA	AA>NNNNNNNN	NNNNNN--	400				
P1-R 150	AA-----	-----	-----	-----	399				
P2-F 151	TGAAGCCCAT	TTGAATGGCA	AA>NNNNNNNN	NNNNNN--	395				
P2-R 152	AANNAT-----	-----	-----	-----	402				
P3-F 153	TGAAGCCCAT	TTGAGTNGCA	AA>NNNNNNNN	NNNNNNNN-	397				
P3-R 154	-----	-----	-----	-----	390				
P4-F 155	TGAAGCCCAT	TTGTGGGCCA	CA>NNNNNNNN	NNNNNNNNN	398				
P4-R 156	-----	-----	-----	-----	392				
	410	420	430						

Exon 3 (ense 00001200259)

P1-F 165	TNTNAANGGA	NGGGNNNTTN	GGNNNTTGGTA	NNNAGGGATG	GGAGGTTNTT	AGNNTANGGG	CGTNGCAAAT	AAAGCAGAAAG
P1-R 166	-----	-----	-----	-----	-----	-----	-----	-----
P2-F 167	-----	-----	-----	-----	-----	-----	-----	-----
P2-R 168	-----	-----	-----	-----	-----	-----	-----	-----
P3-F 169	-----	-----	-----	-----	-----	-----	-----	-----
P3-R 170	-----	-----	-----	-----	-----	-----	-----	-----
P4-F 171	-----	-----	-----	-----	-----	-----	-----	-----
P4-R 172	-----	-----	-----	-----	-----	-----	-----	-----
	10	20	30	40	50	60	70	80
P1-F 165	GGNGGANGAA	GGATTGGTAG	ANNNNGGGAA	ACATTTTNG	ANAANNAAAA	GAGNAGANNA	GTCAGAAAAG	GANAGNGNAT
P1-R 166	-----	-----	-----	-----	-----	-----	-----	-----
P2-F 167	-----	-----	-----	-----	-----	-----	-----	-----
P2-R 168	-----	-----	-----	-----	-----	-----	-----	-----
P3-F 169	-----	-----	-----	-----	-----	-----	-----	-----
P3-R 170	-----	-----	-----	-----	-----	-----	-----	-----
P4-F 171	-----	-----	-----	-----	-----	-----	-----	-----
P4-R 172	-----	-----	-----	-----	-----	-----	-----	-----
	90	100	110	120	130	140	150	160
P1-F 165	TTNAAAAAANG	TTANANNAAG	GGTGGGTGCG	TGTAGGGNCT	GGCANCCCCC	ACTGTGTGTA	ATTGTTCTCT	CTTTAAGTGT
P1-R 166	-----	-----	-----	-----	NNNN	NNNCNCCCCC	ACTGTGTGTA	ATTGTTCTCT
P2-F 167	-----	-----	-----	-----	NNNN	NNNCNCCCCC	ACTGTGTGTA	ATTGTTCTCT
P2-R 168	-----	-----	-----	-----	NNNN	NNNNNNNNNNNN	ACTGTGTGTA	ATTGTTCTCT
P3-F 169	-----	-----	-----	-----	NNNN	NNNNNNNNNNNN	ACTGTGTGTA	ATTGTTCTCT
P3-R 170	-----	-----	-----	-----	NNNN	NNNCNCCCCC	ACTGTGTGTA	ATTGTTCTCT
P4-F 171	-----	-----	-----	-----	NNNN	NNNCNCCCCC	ACTGTGTGTA	ATTGTTCTCT
P4-R 172	-----	-----	-----	-----	NNNN	NNNCNCCCCC	ACTGTGTGTA	ATTGTTCTCT
	170	180	190	200	210	220	230	240
	gtgt	tcatagACTG	GAAAAGTAAG	AAGAGCTTTC				
P1-F 165	TAGGTTATTT	TATAACAGCTT	ACTCAGTTTT	GCCTTTTTCT	CTTTTTGTGT	TCATAGACTG	GAAAAGTAAG	AAGAGCTTTC
P1-R 166	TAGGTTATTT	TATAACAGCTT	ACTCAGTTTT	GCCTTTTTCT	CTTTTTGTGT	TCATAGACTG	GAAAAGTAAG	AAGAGCTTTC
P2-F 167	TAGGTTATTT	TATAACAGCTT	ACTCAGTTTT	GCCTTTTTCT	CTTTTTGTGT	TCATAGACTG	GAAAAGTAAG	AAGAGCTTTC
P2-R 168	TANGTTATTT	TATAACAGCTT	ACTCAGTTTT	GCCTTTTTCT	CTTTTTGTGT	TCATAGACTG	GAAAAGTAAG	AAGAGCTTTC
P3-F 169	TAGGTTATTT	TATAACAGCTT	ACTCAGTTTT	GCCTTTTTCT	CTTTTTGTGT	TCATAGACTG	GAAAAGTAAG	AAGAGCTTTC
P3-R 170	TAGGTTATTT	TATAACAGCTT	ACTCAGTTTT	GCCTTTTTCT	CTTTTTGTGT	TCATAGACTG	GAAAAGTAAG	AAGAGCTTTC
P4-F 171	TAGGTTATTT	TATAACAGCTT	ACTCAGTTTT	GCCTTTTTCT	CTTTTTGTGT	TCATAGACTG	GAAAAGTAAG	AAGAGCTTTC
P4-R 172	TAGGTTATTT	TATAACAGCTT	ACTCAGTTTT	GCCTTTTTCT	CTTTTTGTGT	TCATAGACTG	GAAAAGTAAG	AAGAGCTTTC
	250	260	270	280	290	300	310	320
	CTGCCCTTTTT	AATTACCAAA	CTACTCTCAG	TTTTCATGAA	ATCACTTCAA	AGAAAGAATG	CAGTCCTTCT	ATACCTGGTA
P1-F 165	CTGCCCTTTTT	AATTACCAAA	CTACTCTCAG	TTTTCATGAA	ATCACTTCAA	AGAAAGAATG	CAGTCCTTCT	ATACCTGGTA
P1-R 166	CTGCCCTTTTT	AATTACCAAA	CTACTCTCAG	TTTTCATGAA	ATCACTTCAA	AGAAAGAATG	CAGTCCTTCT	ATACCTGGTA
P2-F 167	CTGCCCTTTTT	AATTACCAAA	CTACTCTCAG	TTTTCATGAA	ATCACTTCAA	AGAAAGAATG	CAGTCCTTCT	ATACCTGGTA
P2-R 168	CTGCCCTTTTT	AATTACCAAA	CTACTCTCAG	TTTTCATGAA	ATCACTTCAG	AGAAAGAATG	CAGTCCTTCT	ATACCTGGTA
P3-F 169	CTGCCCTTTTT	AATTACCAAA	CTACTCTCAG	TTTTCATGAA	ATCACTTCAG	AGAAAGAATG	CAGTCCTTCT	ATACCTGGTA
P3-R 170	CNGCCCTTTTT	AATTACCAAA	CTACTCTCAG	TTTTCATGAA	ATCACTTCAG	AGAAAGAATG	CAGTCCTTCT	ATACCTGGTA
P4-F 171	CTGCCCTTTTT	AATTACCAAA	CTACTCTCAG	TTTTCATGAA	ATCACTTCAG	AGAAAGAATG	CAGTCCTTCT	ATACCTGGTA
P4-R 172	CTGCCCTTTTT	AATTACCAAA	CTACTCTCAG	TTTTCATGAA	ATCACTTCAG	AGAAAGAATG	CAGTCCTTCT	ATACCTGGTA
	330	340	350	360	370	380	390	400
	aatattt							
P1-F 165	AATATTTT--	GGNAAN-AAA	GCNNGNACGG	NNGAANC--	-----	-----	-----	435
P1-R 166	AATATTTTCT	GCTAAATAAA	GCTATTAATT	TAGTAGCATC	TGATAAATCC	AGGTGAGNNN	NNNNNNNNNN	NNNNNN 245
P2-F 167	AATATTTTCT	GCTAAA-AAA	G-	-----	-----	-----	-----	223
P2-R 168	AATATTTTCT	GCTAAATAAA	GCTATTAATT	TAGTAGCATC	TGATAAATCC	AGGTGAGNNN	NNNNNNNNNN	NNNNNN 251
P3-F 169	AAN-TTTTCT	GCTAAA-AAA	GCTATTAATT	-----	-----	-----	-----	246
P3-R 170	AATATTTTCT	GCTAAATAAA	GCTATTAATT	TAGTAGCATC	TGATAAATCC	AGGTGAGNNN	NNNNNNNNNN	NNNNNN 237
P4-F 171	AATATTTTCT	GCTAAA-AAA	G-	-----	-----	-----	-----	222
P4-R 172	AATATTTTCT	GCTAAATAAA	GCTATTAATT	TAGTAGCATC	TGATAAATCC	AGGTGAGNNN	NNNNNNNNNN	NNNNNN 239
	410	420	430	440	450	460	470	

Exon 4 (ense 00001200252)

P1-F 5	-----	-----	-----	TTNNNTNTCTT	TTG-AAATAA	TTATTGATAA	TGCTTGAGGT	
P1-R 6	NNNNNNNNNNN	NNNNNNNNNNN	NNNNTTGTGNG	ATGGGTTTGT	TGGACTTTTT	TTGTAATAA	TGCTTGAGGT	
P2-F 7	-----	-----	-----	-TNNNCCTTT	TTG-AAATAA	TTATTGATAA	TGCTTGAGGT	
P2-R 8	NNNNNNNNNNN	NNNNNNNNNNN	NNNNTTGTGTG	ATGGGTTTGT	TGGACTTTTT	TTGTAATAA	TGCTTGAGGT	
P3-F 9	-----	-----	-----	-TNNNCCTTT	TTG-AAATAA	TTATTGATAA	TGCTTGAGGT	
P3-R 10	NNNNNNNNNNN	NNNNNNNNNNN	NNNNTTGTGNG	ATGGGTTTGT	TGGACTTTTT	TTGTAATAA	TGCTTGAGGT	
P4-F 11	-----	-----	-----	-CTTTT	TTG-AAATAA	TNATTGATAA	TGCTTGAGGT	
P4-R 12	NNNNNNNNNNN	NNNNNNNNNNN	NNNNTTGTGTG	ATGGGTTTGT	TGGACTTTTT	TTGTAATAA	TGCTTGAGGT	
	10	20	30	40	50	60	70	80
P1-F 5	ACTAAAGTATT	TTTATTACAG	AGAATTGAAA	TATCATTAAAG	TGTTTCTGT	AAAGTAAGTTA	ATAGGACACT	AAATTATTGG
P1-R 6	ACTAAAGTATT	TTTATTACAG	AGAATTGAAA	TATCATTAAAG	TGTTTCTGT	AAAGTAAGTTA	ATAGGACACT	AAATTATTGG
P2-F 7	ACTAAAGTATT	TTTATTACAG	AGAATTGAAA	TATCATTAAAG	TGTTTCTGT	AAAGTAAGTTA	ATAGGACACT	AAATTATTGG
P2-R 8	ACTAAAGTATT	TTTATTACAG	AGAATTGAAA	TATCATTAAAG	TGTTTCTGT	AAAGTAAGTTA	ATAGGACACT	AAATTATTGG
P3-F 9	ACTAAAGTATT	TTTATTACAG	AGAATTGAAA	TATCATTAAAG	TGTTTCTGT	AAAGTAAGTTA	ATAGGACACT	AAATTATTGG
P3-R 10	ACTAAAGTATT	TTTATTACAG	AGAATTGAAA	TATCATTAAAG	TGTTTCTGT	AAAGTAAGTTA	ATAGGACACT	AAATTATTGG
P4-F 11	ACTAAAGTATT	TTTATTACAG	AGAATTGAAA	TATCATTAAAG	TGTTTCTGT	AAAGTAAGTTA	ATAGGACACT	AAATTATTGG
P4-R 12	ACTAAAGTATT	TTTATTACAG	AGAATTGAAA	TATCATTAAAG	TGTTTCTGT	AAAGTAAGTTA	ATAGGACACT	AAATTATTGG
	90	100	110	120	130	140	150	160
tggaa aagagATGAA GGTTGGAAAG GATATTGGTG TACTGTTGAG ATTGGCTGGG GTGAAACCAAG TGTTGCTAAA								
P1-F 5	TAGATTGGAA	AAGAGATGAA	GGTTGGAAAG	GATATTGGTG	TACTGTTGAG	ATTGGCTGGG	GTGAAACCAAG	TGTTGCTAAA
P1-R 6	TAGATTGGAA	AAGAGATGAA	GGTTGGAAAG	GATATTGGTG	TACTGTTGAG	ATTGGCTGGG	GTGAAACCAAG	TGTTGCTAAA
P2-F 7	TAGATTGGAA	AAGAGATGAA	GGTTGGAAAG	GATATTGGTG	TACTGTTGAG	ATTGGCTGGG	GTGAAACCAAG	TGTTGCTAAA
P2-R 8	TAGATTGGAA	AAGAGATGAA	GGTTGGAAAG	GATATTGGTG	TACTGTTGAG	ATTGGCTGGG	GTGAAACCAAG	TGTTGCTAAA
P3-F 9	TAGATTGGAA	AAGAGATGAA	GGTTGGAAAG	GATATTGGTG	TACTGTTGAG	ATTGGCTGGG	GTGAAACCAAG	TGTTGCTAAA
P3-R 10	TAGATTGGAA	AAGAGATGAA	GGTTGGAAAG	GATATTGGTG	TACTGTTGAG	ATTGGCTGGG	GTGAAACCAAG	TGTTGCTAAA
P4-F 11	TAGATTGGAA	AAGAGATGAA	GGTTGGAAAG	GATATTGGTG	TACTGTTGAG	ATTGGCTGGG	GTGAAACCAAG	TGTTGCTAAA
P4-R 12	TAGATTGGAA	AAGAGATGAA	GGTTGGAAAG	GATATTGGTG	TACTGTTGAG	ATTGGCTGGG	GTGAAACCAAG	TGTTGCTAAA
	170	180	190	200	210	220	230	240
AGATGCAGAC ACCCCCCCATG ATATAGAAAG GAGgttaacag gca								
P1-F 5	AGATGCAGAC	ACCCCCCATG	ATATAGAAAG	GAGGTAAACAG	GCAATAATTG	TTGAGTCAGA	CATTTCTGCT	TGTTCAACTA
P1-R 6	AGATGCAGAC	ACCCCCCATG	ATATAGAAAG	GAGGTAAACAG	GCAATAATTG	TTGAGTCAGA	CATTTCTGCT	TGTTCAACTA
P2-F 7	AGATGCAGAC	ACCCCCCATG	ATATAGAAAG	GAGGTAAACAG	GCAATAATTG	TTGAGTCAGA	CATTTCTGCT	TGTTCAACTA
P2-R 8	AGATGCAGAC	ACCCCCCATG	ATATAGAAAG	GAGGTAAACAG	GCAATAATTG	TTGAGTCAGA	CATTTCTGCT	TGTTCAACTA
P3-F 9	AGATGCAGAC	ACCCCCCATG	ATATAGAAAG	GAGGTAAACAG	GCAATAATTG	TTGAGTCAGA	CATTTCTGCT	TGTTCAACTA
P3-R 10	AGATGCAGAC	ACCCCCCATG	ATATAGAAAG	GAGGTAAACAG	GCAATAATTG	TTGAGTCAGA	CATTTCTGCT	TGTTCAACTA
P4-F 11	AGATGCAGAC	ACCCCCCATG	ATATAGAAAG	GAGGTAAACAG	GCAATAATTG	TTGAGTCAGA	CATTTCTGCT	TGTTCAACTA
P4-R 12	AGATGCAGAC	ACCCCCCATG	ATATAGAAAG	GAGGTAAACAG	GCAATAATTG	TTGAGTCAGA	CATTTCTGCT	TGTTCAACTA
	250	260	270	280	290	300	310	320
P1-F 5	GTTATATGGT	CA GT TACAGAA	TAGAGGGTAC	AAATGGCTAT	TCATATAGAA	CATGACCAGG	CTGGATGTAA	NNNNCN NNNN
P1-R 6	GTTATATGGT	CA GT TACAGAA	TAGAGGGTAC	AAATGGCTAT	TCAGNGNNNA	A-----	-----	-----
P2-F 7	GTTATATGGT	CA GT TACAGAA	TAGAGGGTAC	AAATGGCTAT	TCATATAGAA	CATGACCAGG	CTGGATGTAA	NNNNCN NNNN
P2-R 8	GTTATATNGT	CA GT TACAGAA	TAGAGGGTAC	AAA-GGCTAT	TCAGNNNNNA	A-----	-----	-----
P3-F 9	GTTATATGGT	CA GT TACAGAA	TAGAGGGTAC	AAATGGCTAT	TCATATAGAA	CATGACCAGG	CTGGATGTAA	NNNNNNNNNN
P3-R 10	GTTATATNGT	CA GT TACAGAA	TAGAGGGTAC	AAA-GGCTAT	TCATATAGAA	CATGACCAGG	CTGGATGTAA	NNNNCN NNNN
P4-F 11	GTTATATGGT	CA GT TACAGAA	TAGAGGGTAC	AAATGGCTAT	TCATATAGAA	CATGACCAGG	CTGGATGTAN	NNNNCN NNNN
P4-R 12	GTTATATNGT	CA GT TACAGAA	TAGAGGGTAC	AAATGGCTAT	TCAGNNNNNA	A-----	-----	-----
	330	340	350	360	370	380	390	400
P1-F 5	358							
P1-R 6	371							
P2-F 7	357							
P2-R 8	369							
P3-F 9	359							
P3-R 10	375							
P4-F 11	353							
P4-R 12	371							

Exon 5 (ense 00001200238)

P1-F 13	-----	-----	-----	-----	TTNNNT	TNNNNNNNNAC	GCAACCCCCC	TCTTTTCGCT	TAAGAACATA
P1-R 14	NNNNNNNNNNN	NNNNNGNTTTG	CTTTTCCCCT	TAATCCACTT	TCCACCCCTAC	GCAACCCCCC	TCTTTTCGCT	TAAGAACATA	
P2-F 15	-----	-----	-----	-----	TTNNNN	TNCACNNNAC	GCAACCCCCC	TCTTTTCGCT	TAAGAACATA
P2-R 16	-NNNNNNNNNN	NNNNNGNTTTG	CTTTTCCCCT	TAATCCACTT	TCCACCCCTAC	GCAACCCCCC	TCTTTTCGCT	TAAGAACATA	
P3-F 17	-----	-----	-----	-----	TTNNNN	TTCCACNNNAC	GCAACCCCCC	TCTTTTCGCT	TAAGAACATA
P3-R 18	NNNNNNNNNNN	NNNNNNNTTTG	CTTTTCCCCT	TAATCCACTT	TCCACCCCTAC	GCAACCCCCC	TCTTTTCGCT	TAAGAACATA	
P4-F 19	-----	-----	-----	-----	TTNNNN	TCCCTNNNTAC	GCAACCCCCC	TCTTTTCGCT	TAAGAACATA
P4-R 20	-NNNNNNNNNN	NNNGGTNTTG	CTTTTCCCCT	TAATCCACTT	TCCACCCCTAC	GCAACCCCCC	TCTTTTCGCT	TAAGAACATA	
	10	20	30	40	50		60	70	80
C-TGTAGATT	TGTTAGAAAT	AGTAGTACCT	TCTTTCCCCA	CCCCAAACTG	CTACCTGTTT	CTTCCTTGTT	TGGACTCTCT		
P1-F 13	C-TGTAGATT	TGTTAGAAAT	AGTAGTACCT	TCTTTCCCCA	CCCCAAACTG	CTACCTGTTT	CTTCCTTGTT	TGGACTCTCT	
P1-R 14	C-TGTAGATT	TGTTAGAAAT	AGTAGTACCT	TCTTTCCCCA	CCCCAAACTG	CTACCTGTTT	CTTCCTTGTT	TGGACTCTCT	
P2-F 15	NC-TGTAGATT	TGTTAGAAAT	AGTAGTACCT	TCTTTCCCCA	CCCCAAACTG	CTACCTGTTT	CTTCCTTGTT	TGGACTCTCT	
P2-R 16	C-TGTAGATT	TGTTAGAAAT	AGTAGTACCT	TCTTTCCCCA	CCCCAAACTG	CTACCTGTTT	CTTCCTTGTT	TGGACTCTCT	
P3-F 17	C-TGTAGATT	TGTTAGAAAT	AGTAGTACCT	TCTTTCCCCA	CCCCAAACTG	CTACCTGTTT	CTTCCTTGTT	TGGACTCTCT	
P3-R 18	C-TGTAGATT	TGTTAGAAAT	AGTAGTACCT	TCTTTCCCCA	CCCCAAACTG	CTACCTGTTT	CTTCCTTGTT	TGGACTCTCT	
P4-F 19	C-TGTAGATT	TGTTAGAAAT	AGTAGTACCT	TCTTTCCCCA	CCCCAAACTG	CTACCTGTTT	CTTCCTTGTT	TGGACTCTCT	
P4-R 20	C-TGTAGATT	TGTTAGAAAT	AGTAGTACCT	TCTTTCCCCA	CCCCAAACTG	CTACCTGTTT	CTTCCTTGTT	TGGACTCTCT	
	90	100	110	120	130		140	150	160
GCTCCTCTAG	AAGATTTCAC	AGCAATGCTG	GACTGCAGTG	ACTATGTTCT	AGgtgggtac	ca			
P1-F 13	GCTCCTCTAG	AAGATTTCAC	AGCAATGCTG	GACTGCAGTG	ACTATGTTCT	AGGTGGGTAC	CAGCACAGTT	CTTTTCTTAG	
P1-R 14	GCTCCTCTAG	AAGATTTCAC	AGCAATGCTG	GACTGCAGTG	ACTATGTTCT	AGGTGGGTAC	CAGCACAGTT	CTTTTCTTAG	
P2-F 15	GCTCCTCTAG	AAGATTTCAC	AGCAATGCTG	GACTGCAGTG	ACTATGTTCT	AGGTGGGTAC	CAGCACAGTT	CTTTTCTTAG	
P2-R 16	GCTCCTCTAG	AAGATTTCAC	AGCAATGCTG	GACTGCAGTG	ACTATGTTCT	AGGTGGGTAC	CAGCACAGTT	CTTTTCTTAG	
P3-F 17	GCTCCTCTAG	AAGATTTCAC	AGCAATGCTG	GACTGCAGTG	ACTATGTTCT	AGGTGGGTAC	CAGCACAGTT	CTTTTCTTAG	
P3-R 18	GCTCCTCTAG	AAGATTTCAC	AGCAATGCTG	GACTGCAGTG	ACTATGTTCT	AGGTGGGTAC	CAGCACAGTT	CTTTTCTTAG	
P4-F 19	GCTCCTCTAG	AAGATTTCAC	AGCAATGCTG	GACTGCAGTG	ACTATGTTCT	AGGTGGGTAC	CAGCACAGTT	CTTTTCTTAG	
P4-R 20	GCTCCTCTAG	AAGATTTCAC	AGCAATGCTG	GACTGCAGTG	ACTATGTTCT	AGGTGGGTAC	CAGCACAGTT	CTTTTCTTAG	
	170	180	190	200	210		220	230	240
P1-F 13	AAAGCTTTAAT	ATGGAAAATAG	AGTGIGTCGG	GTTGACTATG	CAANNNNN	NNNNNNNNNN	-	264	
P1-R 14	AAAGCTTTAAT	ANGAAANNAN	NAANNNA-	-----	-----	-----	-	266	
P2-F 15	AAAGCTTTAAT	ATGGAAAATAG	AGTGIGTCGG	GTTGACTATG	CAANNNNN	NNNNNNNNNN	N	266	
P2-R 16	AAAGCTTTAAT	ANGAAANNAN	NAANNNA-	-----	-----	-----	-	265	
P3-F 17	AAAGCTTTAAT	ATGGAAAATAG	AGTGIGTCGG	GTTGACTATG	CAAAANNNNN	NNNNNNNNNN	N	265	
P3-R 18	AAAGCTTTAAT	ANGAAANNAG	NAANNNA-	-----	-----	-----	-	266	
P4-F 19	AAAGCTTTAAT	ATGGAAAATAG	AGTGIGTCGG	GTTGACTATG	CAAAANNNNN	NNNNNNNNNN	N	264	
P4-R 20	AAAGCTTTAAT	AGGAAGTGAAG	GAATCAA-	-----	-----	-----	-	265	
	250	260	270	280	290		300		

Exon 6 (ense 00000958560)

P1-F 21	-----	-----	-----	-----	-TCTCCCCGT	TTTTTAAAAAA	CCTTATTCTC	
P1-R 22	NNNCNNGNN	NCNGACNNNN	NGCTCAGTTT	TGCCTCCCTCA	ATCCCATCTC	CATCCCCAGT	TTTTTAAAAAA	CCTTATTCTC
P2-F 23	-----	-----	-----	-----	-TNNNTN	CNCTCCCCGT	TTTTTAAAAAA	CCTTATTCTC
P2-R 24	NNNA CNGGNN	NCNGACNGNN	NGCTCAGTTT	TGCCTCCCTCA	ATCCCATCTC	CATCCCCAGT	TTTTTAAAAAA	CCTTATTCTC
P3-F 25	-----	-----	-----	-----	-TTNNNT	CCCTCCCCGT	TTTTTAAAAAA	CCTTATTCTC
P3-R 26	NNNA CNGGNN	NCNGACNGNN	NGCTCAGTTT	TGCCTCCCTCA	ATCCCATCTC	CATCCCCAGT	TTTTTAAAAAA	CCTTATTCTC
P4-F 27	-----	-----	-----	-----	-TNNNTN	NNNTNCCCCGT	TTTTTAAAAAA	CCTTATTCTC
P4-R 28	-NNNA CGGNN	NCNNACNGNN	NGCCCAGTTT	TGCCTCCCTCA	ATCCCAACTC	CATCCCCAGT	TTTTTAAAAAA	CCTTATTCTC
	10	20	30	40	50	60	70	80
ttt attgcagA-C TCAAGAACATGA ACAATCCG-- TCAGAAACCA GTAAACCATC TATGGAGAGT GGAGATGGCA								
C-A-F 173	A-C	TCAAGAACATGA	ACAATCCG-	TCAGAAACCA	GTAAACCATC	TATGGAGAGT	GGAGATGGCA	
C-A-R 174	A-C	TCAAGAACATGA	ACAATCCG-	TCAGAAACCA	GTAAACCATC	TATGGAGAGT	GGAGATGGCA	
C-B-F 175	-----	-----	-----	-----	-----	-----	-----	
C-B-R 176	NNN	NNNNNNNNNNNN	NNNCCCCC--	CCC-AAACCA	GTAAACCATC	TATGGAGAGT	GGAGATGGCA	
P1-F 21	C-TCTGATTT	ATTGCAGA-C	TCAAGAACATGA	ACAATCCG--	TCAGAAACCA	GTAAACCATC	TATGGAGAGT	GGAGATGGCA
P1-R 22	C-TCTGATTT	ATTGCAGA-C	TCAAGAACATGA	ACAATCCG--	TCAGAAACCA	GTAAACCATC	TATGGAGAGT	GGAGATGGCA
P2-F 23	C-TCTGATTT	ATTGCAGA-C	TCAAGAACATGA	ACAATCCG--	TCAGAAACCA	GTAAACCATC	TATGGAGAGT	GGAGATGGCA
P2-R 24	C-TCTGATTT	ATTGCAGA-C	TCAAGAACATGA	ACAATCCG--	TCAGAAACCA	GTAAACCATC	TATGGAGAGT	GGAGATGGCA
P3-F 25	C-TCTGATTT	ATTGCAGA-C	TCAAGAACATGA	ACAATCCG--	TCAGAAACCA	GTAAACCATC	TATGGAGAGT	GGAGATGGCA
P3-R 26	C-TCTGATTT	ATTGCAGA-C	TCAAGAACATGA	ACAATCCG--	TCAGAAACCA	GTAAACCATC	TATGGAGAGT	GGAGATGGCA
P4-F 27	C-TCTGATTT	ATTGCAGA-C	TCAAGAACATGA	ACAATCCG--	TCAGAAACCA	GTAAACCATC	TATGGAGAGT	GGAGATGGCA
P4-R 28	CCTCTGATTT	ATTGCAGAAC	TCAAGAACATGA	ACAATCCCGT	CCAGAAACCA	GTAAACCNC	TANGGAGAGT	GGAGATGGCA
	90	100	110	120	130	140	150	160
ACACAGgtaa gagttt								
C-A-F 173	AAGANN	-----	-----	-----	-----	-----	-----	-----
C-A-R 174	-----	-----	-----	-----	-----	-----	-----	-----
C-B-F 175	ACACAG	-----	-----	-----	-----	-----	-----	-----
C-B-R 176	ACACAG	-----	-----	-----	-----	-----	-----	-----
P1-F 21	ACACAGGTAA	GAGTTTCTG	ATCTAGCTTT	TTAATTAACT	CTAGTAGAGC	ACAAAAGAAGA	AAGTTTCCAT	GTAACACNNN
P1-R 22	ACACAGGTAA	GAGTTTCTG	ATCTAGCTTT	TTAATTAACT	CTAGTAGAGN	GNNAAAGAANN	AA-----	-----
P2-F 23	ACACAGGTAA	GAGTTTCTG	ATCTAGCTTT	TTAATTAACT	CTAGTAGAGC	ACAAAAGAAGA	AAGTTTCCAT	GTAACACNNN
P2-R 24	ACACAGGTAA	GAGTTTCTG	ATCTAGCTTT	TTAATTAACT	CTAGTAGAGN	GNNNNNNNA--	-----	-----
P3-F 25	ACACAGGTAA	GAGTTTCTG	ATCTAGCTTT	TTAATTAACT	CTAGTAGAGC	ACAAAAGAAGA	AAGTTTCCAT	GTAACACNNN
P3-R 26	ACACAGGTAA	GAGTTTCTG	ATCTAGCTTT	TTAATTAACT	CTAGTAGAGN	GNNNNNNNAANN	AA-----	-----
P4-F 27	ACACAGGTAA	GAGTTTCTG	ATCTAGCTTT	TTAATTAACT	CTAGTAGAGN	GNNNNNNNAANN	AA-----	-----
P4-R 28	ACACAGGTAA	GAGTTTNTG	NN-TAGTTT	T--ATTAA-T	NTAGNGGNGN	NNNNNA-----	-----	-----
	170	180	190	200	210	220	230	240
	250	260						

Exon 7 (ense 00001218948)

P1-F 157	-----	-----	-----	-----	-----	-----	CCT	ATTTAAAGACT		
P1-R 158	--NNNNNNNNN	NNNNNNNTNCT	NNTCNCAG-	-ATCGGGT	TTATGATCAG	GACAGGCCCTA	TCTATATCCT	ATTTAAAGACT		
P2-F 159	-----	-----	-----	-----	-----	-----	GAAGGCCCTA	TCTATATCCT	ATTTAAAGACT	
P2-R 160	-----	NNNNNN	NNNNNNNTNNN	NNNTGCAN-	-ATCGGGT	TTATGATCAG	GACAGGCCCTA	TCTATATCCT	ATTTAAAGACT	
P3-F 161	-----	-----	-----	-----	-----	-----	C	NGAAGGCCCTA	TCTATATCCT	ATTTAAAGACT
P3-R 162	--NNNNNNNNN	NNNNNNNTNNT	NNTCNCGC-	-ATCGGGT	TTATGATCAG	GACAGGCCCTA	TCTATATCCT	ATTTAAAGACT		
P4-F 163	-----	-----	-----	-----	-GNNC	NGAAGGCCCTA	TCTATATCCT	ATTTAAAGACT		
P4-R 164	GNNGNNNNNNN	NNNNNNNNNNNT	TTTGCCAAAGG	NCAATCGGGT	TTATGATCAG	GACAGGCCCTA	TCTATATCCT	ATTTAAAGACT		
	10	20	30	40	50	60	70	80		
P1-F 157	ttcttttaca	GCATGGACCC	TTTTATGATA	TGGGCACTGA	AACCTAAAGCA	CATGGTGGAA	GAAGGATTGG			
P1-R 158	GCCTTTTGC	TTCTTTTACA	GCATGGACCC	TTTTATGATA	TGGGCACTGA	AACCTAAAGCA	CATGGTGGAA	GAAGGATTGG		
P2-F 159	GCCTTTTGC	TTCTTTTACA	GCATGGACCC	TTTTATGATA	TGGGCACTGA	AACCTAAAGCA	CATGGTGGAA	GAAGGATTGG		
P2-R 160	GCCTTTTGC	TTCTTTTACA	GCATGGACCC	TTTTATGATA	TGGGCACTGA	AACCTAAAGCA	CATGGTGGAA	GAAGGATTGG		
P3-F 161	GCCTTTTGC	TTCTTTTACA	GCATGGACCC	TTTTATGATA	TGGGCACTGA	AACCTAAAGCA	CATGGTGGAA	GAAGGATTGG		
P3-R 162	GCCTTTTGC	TTCTTTTACA	GCATGGACCC	TTTTATGATA	TGGGCACTGA	AACCTAAAGCA	CATGGTGGAA	GAAGGATTGG		
P4-F 163	GCCTTTTGC	TTCTTTTACA	GCATGGACCC	TTTTATGATA	TGGGCACTGA	AACCTAAAGCA	CATGGTGGAA	GAAGGATTGG		
P4-R 164	GCCTTTTGC	TTCTTTTACA	GCATGGACCC	TTTTATGATA	TGGGCACTGA	AACCTAAAGCA	CATGGTGGAA	GAAGGATTGG		
	90	100	110	120	130	140	150	160		
P1-F 157	TAGCATATAG	AAACATTTTT	AGACAAATGA	AAAAGCAAA	AAAGTCAGAAA	TTACAGTGT	TTTCCATAAA	GTTACACCAA		
P1-R 158	TAGCATATAG	AAAATTTTT	AGACAAATGA	AAAAGCAAA	AAAGTCAGAAA	TTACAGTGT	TTTCCATAAA	GTTACACCAA		
P2-F 159	TAGCATATAG	AAAATTTTT	AGACAAATGA	AAAAGCAAA	AAAGTCAGAAA	TTACAGTGT	TTTCCATAAA	GTTACACCAA		
P2-R 160	TAGCATATAG	AAAATTTTT	AGACAAATGA	AAAAGCAAA	AAAGTCAGAAA	TTACAGTGT	TTTCCATAAA	GTTACACCAA		
P3-F 161	TAGCATATAG	AAAATTTTT	AGACAAATGA	AAAAGCAAA	AAAGTCAGAAA	TTACAGTGT	TTTCCATAAA	GTTACACCAA		
P3-R 162	TAGCATATAG	AAAATTTTT	AGACAAATGA	AAAAGCAAA	AAAGTCAGAAA	TTACAGTGT	TTTCCATAAA	GTTACACCAA		
P4-F 163	TAGCATATAG	AAAATTTTT	AGACAAATGA	AAAAGCAAA	AAAGTCAGAAA	TTACAGTGT	TTTCCATAAA	GTTACACCAA		
P4-R 164	TAGCATATAG	AAAATTTTT	AGACAAATGA	AAAAGCAAA	AAAGTCAGAAA	TTACAGTGT	TTTCCATAAA	GTTACACCAA		
	170	180	190	200	210	220	230	240		
P1-F 157	GTGTGCCTGC	CTCTCCTGCC	TCCCCCTTCCA	GCTTTTTGTC	TTCTGCCATT	TCTGAGTCAG	CAAGACCCCT	CCTGTTCCCTC		
P1-R 158	GTGTGCCTGC	CTCTCCTGCC	TCCCCCTTCCA	GCTTTTTGTC	TTCTGCCATT	TCTGAGTCAG	CAAGACCCCT	CCTGTTCCCTC		
P2-F 159	GTGTGCCTGC	CTCTCCTGCC	TCCCCCTTCCA	GCTTTTTGTC	TTCTGCCATT	TCTGAGTCAG	CAAGACCCCT	CCTGTTCCCTC		
P2-R 160	GTGTGCCTGC	CTCTCCTGCC	TCCCCCTTCCA	GCTTTTTGTC	TTCTGCCATT	TCTGAGTCAG	CAAGACCCCT	CCTGTTCCCTC		
P3-F 161	GTGTGCCTGC	CTCTCCTGCC	TCCCCCTTCCA	GCTTTTTGTC	TTCTGCCATT	TCTGAGTCAG	CAAGACCCCT	CCTGTTCCCTC		
P3-R 162	GTGTGCCTGC	CTCTCCTGCC	TCCCCCTTCCA	GCTTTTTGTC	TTCTGCCATT	TCTGAGTCAG	CAAGACCCCT	CCTGTTCCCTC		
P4-F 163	GTGTGCCTGC	CTCTCCTGCC	TCCCCCTTCCA	GCTTTTTGTC	TTCTGCCATT	TCTGAGTCAG	CAAGACCCCT	CCTGTTCCCTC		
P4-R 164	GTGTGCCTGC	CTNTCCTGCC	TCCCCCTTCCA	GCTTTTTGTC	TTCTGCCATT	TCTGAGTCAG	CAAGACCCCT	CCTGTTCCCTC		
	250	260	270	280	290	300	310	320		
P1-F 157	CTTCTCAGCC	TACTCAGCAT	GAAGACAAGG	ATGAAGATCT	TTGTGATGAT	CCACTTCCAC	TTAATGAATA	gtaaatata		
P1-R 158	CTTCTCAGCC	TACTCAGCAT	GAAGACAAGG	ATGAAGATCT	TTGTGATGAT	CCACTTCCAC	TTAATGAATA	GTAAATATAT		
P2-F 159	CTTCTCAGCC	TACTCAGCAT	GAAGACAAGG	ATGAAGATCT	TTGTGATGAT	CCACTTCCAC	TTAATGAATA	GTAAATATAT		
P2-R 160	CTTCTCAGCC	TACTCAGCAT	GAAGACAAGG	ATGAAGATCT	TTGTGATGAT	CCACTTCCAC	TTAATGAATA	GTAAATATAT		
P3-F 161	CTTCTCAGCC	TACTCAGCAT	GAAGACAAGG	ATGAAGATCT	TTGTGATGAT	CCACTTCCAC	TTAATGAATA	GTAAATATAT		
P3-R 162	CTTCTCAGCC	TACTCAGCAT	GAAGACAAGG	ATGAAGATCT	TTGTGATGAT	CCACTTCCAC	TTAATGAATA	GTAAATATAT		
P4-F 163	CTTCTCAGCC	TACTCAGCAT	GAAGACAAGG	ATGAAGATCT	TTGTGATGAT	CCACTTCCAC	TTAATGAATA	GTAAATATAT		
P4-R 164	CTTCTCAGCC	TACTCAGCAT	GAAGACAAGG	ATGAAGATCT	TTGTGATGAT	CCACTTCCAC	TTAATGAATA	GTAAACNTAT		
	330	340	350	360	370	380	390	400		
P1-F 157	TTTCTCTCAC	TTAGGATTTT	CTTTAGCTTA	CTTTACTGTA	AGAAATACAGT	ATATAATACA	TATACAAATA	TGTTTTAGTC		
P1-R 158	TTTCTCTCAC	TTAGGATTTT	CTTTAGCTTA	CTTTACTGTA	AGAAATACAGT	ATATAATACA	TATACAAATA	TGTTNGTNNN		
P2-F 159	TTTCTCTCAC	TTAGGATTTT	CTTTAGCTTA	CTTTACTGTA	AGAAATACAGT	ATATAATACA	TATACAAATA	TGTTTTAGTC		
P2-R 160	TTTCTCTCAC	TTAGGATTTT	CTTTAGCTTA	CTTTACTGTA	AGAAATACAGT	ATATAATACA	TATACAAATA	TGTTTTAGTC		
P3-F 161	TTTCTCTCAC	TTAGGATTTT	CTTTAGCTTA	CTTTACTGTA	AGAAATACAGT	ATATAATACA	TATACAAATA	TGTTTTAGTC		
P3-R 162	TTTCTCTCAC	TTAGGATTTT	CTTTAGCTTA	CTTTACTGTA	AGAAATACAGT	ATATAATACA	TATACAAATA	TGTTTTAGTC		
P4-F 163	TTTCTCTCAC	TTAGGATTTT	CTTTAGCTTA	CTTTACTGTA	AGAAATACAGT	ATATAATACA	TATACAAATA	TGTTTTAGTC		
P4-R 164	TTTCTCTCAC	TTAGGATTTT	CTTTAGCTTA	CTTTACTGTA	AGAAATACAGT	ATATAATACA	TA-ACAAATN	GNNNNNNNNN		
	410	420	430	440	450	460	470	480		
P1-F 157	AACTGTTAT	GTTATCAGCA	ATGCTTNGA	AAAANNNNNN	NNNN-----	457				
P1-R 158	NNNNNNNNNN	A-----	-----	-----	-----	484				
P2-F 159	AACTGTTAT	GTTATCAGCA	ATGCTTNGCA	ANAANNNNNN	NNN-----	472				
P2-R 160	AAC	-----	-----	-----	-----	473				
P3-F 161	AACTGTTAT	GTTATCAGCA	ATGCTNGCNA	ANAANNNNNN	NNN-----	474				
P3-R 162	AAC	-----	-----	-----	-----	476				
P4-F 163	AACTGTTAT	GTTATCAGCA	ATGCTNGTN	ANNNANNNNNN	NNNNNNNNNN	484				
P4-R 164	NNNNNNNNNN	AA-----	-----	-----	-----	491				
	490	500	510	520	530					

Exon 8 (ense 00000958561)

(P3-F 33 sequence was non-specific only the reverse sequence is included)

P1-F 183	-----	-----	-----	-----	-----	TTNNACCN	NNNNATGCTT	-ATTTA-TTT	ATTTCTTTTA
P1-R 184	NNNNNNNNNNN	NNNNNNNNNNN	TTGGTGCGCTG	ATGAATGTTG	GTAACTGAAA	TCTAGTGCTT	TATTTCATTT	ATTTCTTTTA	
P2-F 31	-----	-----	-----	-----	-----	NNNNNA	NTCTATGCTT	TATTTA-TTT	ATTTCTTTTA
P2-R 32	NNNNNNNNNNN	NNNNNNNNNNN	TTGGTGCGCTG	ATGAATGTTG	GTAACTGAAA	TCTAGTGCTT	TATTTCATTT	ATTTCTTTTA	
P3-R 34	NNNNNNNNNNN	NNNNNNNNNNN	TTGGTGCGCTG	ATGAATGTTG	GTAACTGAAA	TCTAGTGCTT	TATTTCATTT	ATTTCTTTTA	
P4-F 35	-----	-----	-----	-----	-----	AA	TCTAGTGCTT	TATTTNATTN	ATTTCTTTTA
P4-R 36	NNNNNNNNNNN	NNNNNNNNNNN	TTGGTGCGCTG	ATGAATGTTG	GTAACTGAAA	TCTAGTGCTT	TATTTCATTT	ATTTCTTTTA	
	10	20	30	40	50	60	70	80	
REF	tgctttctag	GCACACAAAC	CAATGGCTCG	GACTTTCAGA	AGCAGCCTGT	GCCTGTAGGA			
C-B-F 175	GGAGCAATCT	CAACAGCCCCA	GGCGCAGGCT	TTCCCTGGAC	ATCTCCATCA	Ggttaggaatg t			
C-B-R 176	GGAGCAATCT	CAACAGCCCCA	GGCGCAGGCT	TTCCCTGGAC	ATCTCCATCA	G			
P1-F 183	ATAGTTGAAA	TTATTTTGC	TGCTTTCTAG	GCACACAAAC	CAATGGCTCG	GACTTTCAGA	AGCAGCCTGT	GCCTGTAGGA	
P1-R 184	ATAGTTGAAA	TTATTTTGC	TGCTTTCTAG	GCACACAAAC	CAATGGCTCG	GACTTTCAGA	AGCAGCCTGT	GCCTGTAGGA	
P2-F 31	ATAGTTGAAA	TTATTTTGC	TGCTTTCTAG	GCACACAAAC	CAATGGCTCG	GACTTTCAGA	AGCAGCCTGT	GCCTGTAGGA	
P2-R 32	ATAGTTGAAA	TTATTTTGC	TGCTTTCTAG	GCACACAAAC	CAATGGCTCG	GACTTTCAGA	AGCAGCCTGT	GCCTGTAGGA	
P3-R 34	ATAGTTGAAA	TTATTTTGC	TGCTTTCTAG	GCACACAAAC	CAATGGCTCG	GACTTTCAGA	AGCAGCCTGT	GCCTGTAGGA	
P4-F 35	ATAGTTGAAA	TTATTTTGC	TGCTTTCTAG	GCACACAAAC	CAATGGCTCG	GACTTTCAGA	AGCAGCCTGT	GCCTGTAGGA	
P4-R 36	ATAGTTGAAA	TTATTTTGC	TGCTTTCTAG	GCACACAAAC	CAATGGCTCG	GACTTTCAGA	AGCAGCCTGT	GCCTGTAGGA	
	90	100	110	120	130	140	150	160	
	GGAGCAATCT	CAACAGCCCCA	GGCGCAGGCT	TTCCCTGGAC	ATCTCCATCA	Ggttaggaatg t			
C-B-F 175	GGAGCAATCT	CAACAGCCCCA	GGCGCAGGCT	TTCCCTGGAC	ATCTCCATCA	G			
C-B-R 176	GGAGCAATCT	CAACAGCCCCA	GGCGCAGGCT	TTCCCTGGAC	ATCTCCATCA	G			
P1-F 183	GGAGCAATCT	CAACAGCCCCA	GGCGCAGGCT	TTCCCTGGAC	ATCTCCATCA	GGTAGGAATG	TTCTGCTCAA	CCATCAGTGA	
P1-R 184	GGAGCAATCT	CAACAGCCCCA	GGCGCAGGCT	TTCCCTGGAC	ATCTCCATCA	GGTAGGAATG	TTCTGCTCAA	CCATCAGTGA	
P2-F 31	GGAGCAATCT	CAACAGCCCCA	GGCGCAGGCT	TTCCCTGGAC	ATCTCCATCA	GGTAGGAATG	TTCTGCTCAA	CCATCAGTNA	
P2-R 32	GGAGCAATCT	CAACAGCCCCA	GGCGCAGGCT	TTCCCTGGAC	ATCTCCATCA	GGTAGGAATG	TTCTGCTCAA	CCATCAGN-A	
P3-R 34	GGAGCAATCT	CAACAGCCCCA	GGCGCAGGCT	TTCCCTGGAC	ATCTCCATCA	GGTAGGAATG	TTCTGCTCAA	CCATCAGTGA	
P4-F 35	GGAGCAATCT	CAACAGCCCCA	GGCGCAGGCT	TTCCCTGGAC	ATCTCCATCA	GGTAGGAATG	TTCTGCTCAA	CCATCAGTGA	
P4-R 36	GGAGCAATCT	CAACAGCCCCA	GGCGCAGGCT	TTCCCTGGAC	ATCTCCATCA	GGTAGGAATG	TTCTGCTCAA	CCATCAGTGA	
	170	180	190	200	210	220	230	240	
P1-F 183	GAGTGAAAGA	TAGAGGCGTA	AAGTACTGGG	NGCTGAAANN	NNNNNN-----	-----	-----	-----	241
P1-R 184	GAGNAAAGAN	GNGGNANCANA	-----	-----	-----	-----	-----	-----	260
P2-F 31	GAGTGAAAGA	TANAGGCGTA	AAGTACTGGG	GCCCTGAACC	ANNNNNNNNNN	NNNNNNNNNNN	NN	256	
P2-R 32	GAGTGAAAGN	AAG-----	-----	-----	-----	-----	-----	-----	253
P3-R 34	GAGNAAAGAN	G-----	-----	-----	-----	-----	-----	-----	250
P4-F 35	GAGTGAAAGA	TAGAGGCGTA	AAGTACTGGG	NNCTGAAANN	NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	NNNNNNNNNN	252
P4-R 36	GAGTAAAGA-	-----	-----	-----	-----	-----	-----	-----	249
	250	260	270	280	290	300			

Exon 9 (ense 00000958562)

P1-F 37	-----	-----	-----	TTA	ANGGNTGAGC	TTGTTCATAA	AGTTTTAACT	CCGTAAGACA	AACTTCCTTG
P1-R 38	-NNNNNNNNN	TTTGGGNTNN	TGGTTGAGAA	GGGACTGAGC	TTGTTCATAA	AGTTTTAACT	CCGTAAGACA	AACTTCCTTG	
P2-F 39	-----	-----	-----	TAA	ANGGNTGAGC	TTGTTCATAA	AGTTTTAACT	CCGTAAGACA	AACTTCCTTG
P2-R 40	-NNNNNNNNNT	TTGGGGGTNN	TGGTTGAGAA	GGGACTGAGC	TTGTTCATAA	AGTTTTAACT	CCGTAAGACA	AACTTCCTTG	
P3-F 41	-----	-----	-----	TAATNAAA	NGGNCTGAGC	TTGTTCATAA	AGTTTTAACT	CCGTAAGACA	AACTTCCTTG
P3-R 42	NNNNNNNNNT	TTGGGGNNNC	TGGTTGAGAA	GGGACTGAGC	TTGTTCATAA	AGTTTTAACT	CCGTAAGACA	AACTTCCTTG	
P4-F 43	-----	-----	-----	TNN	NNGGNTGAGC	TTGTTCATAA	AGTTTTAACT	CCGTAAGACA	AACTTCCTTG
P4-R 44	-NNNNNNNNNT	TTGGGGGTNC	TGGTTGAGAA	GGGACTGAGC	TTGTTCATAA	AGTTTTAACT	CCGTAAGACA	AACTTCCTTG	
	10	20	30	40	50	60	70	80	
P1-F 37	TCTTCTCAGT	TCTAGCTCGG	TGACACATAG	TAGACCTTTAT	TTAGTGTATGA	CAACCCCTTG	TGATGAATGT	CAACAGTATT	
P1-R 38	TCTTCTCAGT	TCTAGCTCGG	TGACACATAG	TAGACCTTTAT	TTAGTGTATGA	CAACCCCTTG	TGATGAATGT	CAACAGTATT	
P2-F 39	TCTTCTCAGT	TCTAGCTCGG	TGACACATAG	TAGACCTTTAT	TTAGTGTATGA	CAACCCCTTG	TGATGAATGT	CAACAGTATT	
P2-R 40	TCTTCTCAGT	TCTAGCTCGG	TGACACATAG	TAGACCTTTAT	TTAGTGTATGA	CAACCCCTTG	TGATGAATGT	CAACAGTATT	
P3-F 41	TCTTCTCAGT	TCTAGCTCGG	TGACACATAG	TAGACCTTTAT	TTAGTGTATGA	CAACCCCTTG	TGATGAATGT	CAACAGTATT	
P3-R 42	TCTTCTCAGT	TCTAGCTCGG	TGACACATAG	TAGACCTTTAT	TTAGTGTATGA	CAACCCCTTG	TGATGAATGT	CAACAGTATT	
P4-F 43	TCTTCTCAGT	TCTAGCTCGG	TGACACATAG	TAGACCTTTAT	TTAGTGTATGA	CAACCCCTTG	TGATGAATGT	CAACAGTATT	
P4-R 44	TCTTCTCAGT	TCTAGCTCGG	TGACACATAG	TAGACCTTTAT	TTAGTGTATGA	CAACCCCTTG	TGATGAATGT	CAACAGTATT	
	90	100	110	120	130	140	150	160	
C-B-F 175	t	tacttatacg	TCCAACTCGC	TGGAACAAGT	TTACAGGCTG	CTGCTCAGTC	TTTAAATGTA		
C-B-R 176		G	TCCAACTCGC	TGGAACAAGT	TTACAGGCTG	CTGCTCAGTC	TTTAAATGTA		
P1-F 37	AAACTAGAAC	TTCCCCCTGAT	TACTTATAGG	TCCAACTCGC	TGGAACAAGT	TTACAGGCTG	CTGCTCAGTC	TTTAAATGTA	
P1-R 38	AAACTAGAAC	TTCCCCCTGAT	TACTTATAGG	TCCAACTCGC	TGGAACAAGT	TTACAGGCTG	CTGCTCAGTC	TTTAAATGTA	
P2-F 39	AAACTAGAAC	TTCCCCCTGAT	TACTTATAGG	TCCAACTCGC	TGGAACAAGT	TTACAGGCTG	CTGCTCAGTC	TTTAAATGTA	
P2-R 40	AAACTAGAAC	TTCCCCCTGAT	TACTTATAGG	TCCAACTCGC	TGGAACAAGT	TTACAGGCTG	CTGCTCAGTC	TTTAAATGTA	
P3-F 41	AAACTAGAAC	TTCCCCCTGAT	TACTTATAGG	TCCAACTCGC	TGGAACAAGT	TTACAGGCTG	CTGCTCAGTC	TTTAAATGTA	
P3-R 42	AAACTAGAAC	TTCCCCCTGAT	TACTTATAGG	TCCAACTCGC	TGGAACAAGT	TTACAGGCTG	CTGCTCAGTC	TTTAAATGTA	
P4-F 43	AAACTAGAAC	TTCCCCCTGAT	TACTTATAGG	TCCAACTCGC	TGGAACAAGT	TTACAGGCTG	CTGCTCAGTC	TTTAAATGTA	
P4-R 44	AAACTAGAAC	TTCCCCCTGAT	TACTTATAGG	TCCAACTCGC	TGGAACAAGT	TTACAGGCTG	CTGCTCAGTC	TTTAAATGTA	
	170	180	190	200	210	220	230	240	
C-B-F 175	CAGgtaaagct	ggg							
C-B-R 176	CAG								
P1-F 37	CAGGTAAGCT	GGGACCTGGG	ATTATGGGTC	AATCTTTAT	TTATTTTTTC	TTATTTTTTC	CTGTAGTGAG	CATATATTTT	
P1-R 38	CAGGTAAGCT	GGGACCTGGG	ATTATGGGTC	AATCTTTAT	TTATTTTTTC	TTATTTTTTC	CTGTAGTGAG	CATATATTTT	
P2-F 39	CAGGTAAGCT	GGGACCTGGG	ATTATGGGTC	AATCTTTAT	TTATTTTTTC	TTATTTTTTC	CTGTAGTGAG	CATATATTTT	
P2-R 40	CAGGTAAGCT	GGGACCTGGG	ATTATGGGTC	AATCTTTAT	TTATTTTTTC	TTATTTTTTC	CTGTAGTGAG	CATATATTTT	
P3-F 41	CAGGTAAGCT	GGGACCTGGG	ATTATGGGTC	AATCTTTAT	TTATTTTTTC	TTATTTTTTC	CTGTAGTGAG	CATATATTTT	
P3-R 42	CAGGTAAGCT	GGGACCTGGG	ATTATGGGTC	AATCTTTAT	TTATTTTTTC	TTATTTTTTC	CTGTAGTGAG	CATATATTTT	
P4-F 43	CAGGTAAGCT	GGGACCTGGG	ATTATGGGTC	AATCTTTAT	TTATTTTTTC	TTATTTTTTC	CTGTAGTGAG	CATATATTTT	
P4-R 44	CAGGTAAGCT	GGGACCTGGG	ATTATGGGTC	AATCTTTAT	TTATTTTTTC	TTATTTTTTC	CTGTAGTGAG	CATATATTTT	
	250	260	270	280	290	300	310	320	
P1-F 37	ATAATAGGAA	ATGCTTAGAA	GTATTACCTT	TTCAAAATTA	GTGAATCTCG	TGAAGATTCA	AATAATGATA	ATTATTACCA	
P1-R 38	ATAATAGGAA	ATGCTTAGAA	GTATTACCTT	TTCAAAATTA	GTGAATCTCG	TGAAGATTCA	AATAATGATA	ATTATTACCA	
P2-F 39	ATAATAGGAA	ATGCTTAGAA	GTATTACCTT	TTCAAAATTA	GTGAATCTCG	TGAAGATTCA	AATAATGATA	ATTATTACCA	
P2-R 40	ATAATAGGAA	ATGCTTAGAA	GTATTACCTT	TTCAAAATTA	GTGAATCTCG	TGAAGATTCA	AATAATGATA	ATTATTACCA	
P3-F 41	ATAATAGGAA	ATGCTTAGAA	GTATTACCTT	TTCAAAATTA	GTGAATCTCG	TGAAGATTCA	AATAATGATA	ATTATTACCA	
P3-R 42	ATAATAGGAA	ATGCTTAGAA	GTATTACCTT	TTCAAAATTA	GTGAATCTCG	TGAAGATTCA	AATAATGATA	ATTATTACCA	
P4-F 43	ATAATAGGAA	ATGCTTAGAA	GTATTACCTT	TTCAAAATTA	GTGAATCTCG	TGAAGATTCA	AATAATGATA	ATTATTACCA	
P4-R 44	ATAATAGGAA	ATGCTTAGAA	GTATTACCTT	TTCAAAATTA	GTGAATCTCG	TGAAGATTCA	AATAATGATA	ATTATTACCA	
	330	340	350	360	370	380	390	400	
P1-F 37	TTAATGAAAA	TCAGTTTTAT	ATTATGCTAC	TGIGCATGAA	CCAAAAACNN	GGANANANNN	NNN-	436	
P1-R 38	TTAATGAAAA	TCAGTTTTAT	ATT-NGNNNN	NNGNNNA	-----	-----	-----	435	
P2-F 39	TTAATGAAAA	TCAGTTTTAT	ATTNTGCTAC	TGIGCATGAA	CCAAAAAGGG	GGAAAAANNN	NNNN	437	
P2-R 40	TTAAT-AAAA	TCAGTTTTAT	ATT-NGCNAC	-----	-----	-----	-----	427	
P3-F 41	TTAATGAAAA	TCAGTTTTAT	ATTNTGCTAC	TGIGCATGAA	CCAAAAATGN	GGGGAAAANN	NNNN	442	
P3-R 42	TTAATTAAAA	TCAGTTTTAT	ATTATGCNNC	NCNGNNNANA	A-----	-----	-----	441	
P4-F 43	TTAATGAAAA	TCAGTTTTAT	ATTCTGCTAC	TGIGCATGAA	CCAAAAACNG	GGGAAAANN	NNN-	436	
P4-R 44	TTAATTAAAA	TCAGTTTTAT	ATT-CGNNGG	NNGNCANAA	-----	-----	-----	438	
	410	420	430	440	450	460			

Exon 10 (ense 00000958563)

P1-F 45	-----	-----	-----	TNTNTTGANN	NCNTACATTT	CTTTTAATCA	ACNATTGCA	ATCTTTTATT
P1-R 46	NNNNNNNNNN	NNNNNNNTTGA	TTCCCTAAAAG	ATGGGGTTTT	AAGTACATTT	CTTTTAATCA	ACCATTGCA	ATCTTTTATT
P2-F 47	-----	-----	-----	-TTTTTNCCN	AAGTACATTT	CTTTTA--AT	NACCTTTGCA	ATCTTTTATT
P2-R 48	NNANGANNGC	NNATNGTTGA	TTCCCTAAAAG	ATGGGGTTTT	AAGTACATTT	CTTTTAATCA	ACCATTGCA	ATCTTTTATT
P3-F 49	-----	-----	-----	TNTNNNN	NNANGTNATT	TTTTTA--TN	ACCATTGCA	ATCTTTTATT
P3-R 50	NNANGANNGC	NNANNNGTTGA	TTCCCTAAAAG	ATGGGGTTTT	AAGTACATTT	CTTTTAATCA	ACCATTGCA	ATCTTTTATT
P4-F 51	-----	-----	-----	-TNTTGNCNN	AAGTACATTT	CTTTTAATNA	ACCATTGCA	ATCTTTTATT
P4-R 52	NNAAGANNGC	NANTNGTTGA	TTCCCTAAAAG	ATGGGGTTTT	AAGTACATTT	CTTTTAATCA	ACCATTGCA	ATCTTTTATT
	10	20	30	40	50	60	70	80
REF	cccacctcg	TCTAAATCTA	ATGAAGAAC	GGGGGATTCG	CAGCAGCCAA	GCCAGCCTTC	CCAGCAGCCT	
C-B-F 175	TCTAAATCTA	ATGAAGAAC	GGGGGATTCG	CAGCAGCCAA	GCCAGCCTTC	CCAGCAGCCT		
C-B-R 176	TCTAAATCTA	ATGAAGAAC	GGGGGATTCG	CAGCAGCCAA	GCCAGCCTTC	CCAGCAGCCT		
P1-F 45	TCCTACCCAC	CCCACCTCAG	TCTAAATCTA	ATGAAGAAC	GGGGGATTCG	CAGCAGCCAA	GCCAGCCTTC	CCAGCAGCCT
P1-R 46	TCCTACCCAC	CCCACCTCAG	TCTAAATCTA	ATGAAGAAC	GGGGGATTCG	CAGCAGCCAA	GCCAGCCTTC	CCAGCAGCCT
P2-F 47	TCCTACCCAC	CCCACCTCAG	TCTAAATCTA	ATGAAGAAC	GGGGGATTCG	CAGCAGCCAA	GCCAGCCTTC	CCAGCAGCCT
P2-R 48	TCCTACCCAC	CCCACCTCAG	TCTAAATCTA	ATGAAGAAC	GGGGGATTCG	CAGCAGCCAA	GCCAGCCTTC	CCAGCAGCCT
P3-F 49	TCCTACCCAC	CCCACCTCAG	TCTAAATCTA	ATGAAGAAC	GGGGGATTCG	CAGCAGCCAA	GCCAGCCTTC	CCAGCAGCCT
P3-R 50	TCCTACCCAC	CCCACCTCAG	TCTAAATCTA	ATGAAGAAC	GGGGGATTCG	CAGCAGCCAA	GCCAGCCTTC	CCAGCAGCCT
P4-F 51	TCCTACCCAC	CCCACCTCAG	TCTAAATCTA	ATGAAGAAC	GGGGGATTCG	CAGCAGCCAA	GCCAGCCTTC	CCAGCAGCCT
P4-R 52	TCCTACCCAC	CCCACCTCAG	TCTAAATCTA	ATGAAGAAC	GGGGGATTCG	CAGCAGCCAA	GCCAGCCTTC	CCAGCAGCCT
	90	100	110	120	130	140	150	160
	TCAGTGCAGG	CAGCCATTCC	CCAGACCCAG	CTTATGCTAG	CTGGAGGACA	GATAACTGGG	gtaagtgttc	
C-B-F 175	TCAGTGCAGG	CAGCCATTCC	CCAGACCCAG	CTTATGCTAG	CTGGAGGACA	GATAACTGGG		
C-B-R 176	TCAGTGCAGG	CAGCCATTCC	CCAGACCCAG	CTTATGCTAG	CTGGAGGACA	GATAACTGGG		
P1-F 45	TCAGTGCAGG	CAGCCATTCC	CCAGACCCAG	CTTATGCTAG	CTGGAGGACA	GATAACTGGG	GTAAGTGTTC	ACTGAGAGAA
P1-R 46	TCAGTGCAGG	CAGCCATTCC	CCAGACCCAG	CTTATGCTAG	CTGGAGGACA	GATAACTGGG	GTAAGTGTTC	ACG-AGAGAA
P2-F 47	TCAGTGCAGG	CAGCCATTCC	CCAGACCCAG	CTTATGCTAG	CTGGAGGACA	GATAACTGGG	GTAAGTGTTC	ACTGAGAGAA
P2-R 48	TCAGTGCAGG	CAGCCATTCC	CCAGACCCAG	CTTATGCTAG	CTGGAGGACA	GATAACTGGG	GTAAGTGTTC	ACN-AGAGAA
P3-F 49	TCAGTGCAGG	CAGCCATTCC	CCAGACCCAG	CTTATGCTAG	CTGGAGGACA	GATAACTGGG	GTAAGTGTTC	ACTGAGAGAA
P3-R 50	TCAGTGCAGG	CAGCCATTCC	CCAGACCCAG	CTTATGCTAG	CTGGAGGACA	GATAACTGGG	GTAAGTGTTC	ACG-AGAGAA-
P4-F 51	TCAGTGCAGG	CAGCCATTCC	CCAGACCCAG	CTTATGCTAG	CTGGAGGACA	GATAACTGGG	GTAAGTGTTC	ACTGAGAGAA
P4-R 52	TCAGTGCAGG	CAGCCATTCC	CCAGACCCAG	CTTATGCTAG	CTGGAGGACA	GATAACTGGG	GTAAGTGTTC	ACTGAGAGAA
	170	180	190	200	210	220	230	240
P1-F 45	TTATAACAAA	CTTTTTCTGT	GTCAGAACTG	CCATTGGANN	NNNNNNNNNN	NN--	262	
P1-R 46	GGATN-CGGN	NG--NCAAAA	-----	-----	-----	-----	256	
P2-F 47	TTATAACAAA	CTTTTTCTGT	GTCAGAACTG	CCATTGGAAAN	NNNNNNNNNN	NNN-	260	
P2-R 48	TTATAACAAA	CNGTTCANAA	-----	-----	-----	-----	259	
P3-F 49	TTATAACAAA	CTTTTTCTGT	GTCAGAACTG	CCATTGGAN	NNNNNNNNNN	NNNN	259	
P3-R 50	-----	-----	-----	-----	-----	-----	238	
P4-F 51	TTATAACAAA	CTTTTTCTGT	GTCAGAACTG	CCATTGGAAA	NNNNNNNNNN	NN--	262	
P4-R 52	TTATAACAAA	CT-TTCANAA	-----	-----	-----	-----	259	
	250	260	270	280	290			

Exon 11 (ense 00000958564)

Exon 12 (ense 00000958565)

P1-F 61	-----	-----	-----	-----	-----	ANCA	ACTTTAT---	TTANAATCTC	NA-TCNATGT
P1-R 62	NNNNNNNNNN	NTTTCCAGAA	ATCATCAGCT	GGAAGCCTTA	TAATTAAGCG	AACTTTTATT	TCAGAATCTC	CAATCCATGT	
P2-F 63	-----	-----	-----	-----	-----	AGCG	AACTTTTATT	TCAGAATCTC	CA-TCNATGT
P2-R 64	NNNNNNNNNN	NTNTCCAGAA	AGCATCAGCT	GGAAGCCTTA	TAATTAAGCG	AACTTTTATT	TCAGAATCTC	CAATCCATGT	
P3-F 65	-----	-----	-----	-----	CN NNNATTAGCG	ANCTTTTATT	TNAGAATCTC	CAATCCATGT	
P3-R 66	NNNNNNNNNN	NTTTCCAGAA	ATCATCAGCT	GGAAGCCTTA	TAATTAAGCG	ANCTTTTATT	TCAGAATCTC	CAATCCATGT	
P4-F 67	-----	-----	-----	-----	TANCA	ACTTTAT--	TTANAATCTC	CA-TCNATGT	
P4-R 68	-NNNNNNNNNN	NNNTCCAGAN	AGCATCAGCT	GGAAGCCTTA	TAATTAAGCG	ANCTTTTATT	TCAGAATCTC	CAATCCATGT	
	10	20	30	40	50	60	70	80	
	a atttttcagg	ATCTTCAACA	ACTGCAACAG	CTTCAACAGC	AGAATCTCAA	CCTGCAACAG	TTTGTTGG		
C-C-F 177	-----	G	ATCTTCAACA	ACTGCAACAG	CTTCAACAGC	AGAATCTCAA	CCTGCAACAG	TTTGTTGG	
C-C-R 178	-----	G	ATCTTCAACA	ANTGCAACAG	CTTCAACAGC	AGAATCTCAA	CCTGCAACAG	TTTGTTGG	
P1-F 61	TTTAATTCCA	-TTTTTCAGG	ATCTTCAACA	ACTGCAACAG	CTTCAACAGC	AGAATCTCAA	CCTGCAACAG	TTTGTTGG	
P1-R 62	TTTAATTCCA	ATTTTTCAGG	ATCTTCAACA	ACTGCAACAG	CTTCAACAGC	AGAATCTCAA	CCTGCAACAG	TTTGTTGG	
P2-F 63	TTTAATTCCA	ATTTTTCAGG	ATCTTCAACA	ACTGCAACAG	CTTCAACAGC	AGAATCTCAA	CCTGCAACAG	TTTGTTGG	
P2-R 64	TTTAATTCCA	ATTTTTCAGG	ATCTTCAACA	ACTGCAACAG	CTTCAACAGC	AGAATCTCAA	CCTGCAACAG	TTTGTTGG	
P3-F 65	TTTAATTCCA	ATTTTTCAGG	ATCTTCAACA	ACTGCAACAG	CTTCAACAGC	AGAATCTCAA	CCTGCAACAG	TTTGTTGG	
P3-R 66	TTTAATTCCA	ATTTTTCAGG	ATCTTCAACA	ACTGCAACAG	CTTCAACAGC	AGAATCTCAA	CCTGCAACAG	TTTGTTGG	
P4-F 67	TTTAATTCCA	ATTTTTCAGG	ATCTTCAACA	ACTGCAACAG	CTTCAACAGC	AGAATCTCAA	CCTGCAACAG	TTTGTTGG	
P4-R 68	TTTAATTCCA	ATTTTTCAGG	ATCTTCAACA	ACTGCAACAG	CTTCAACAGC	AGAATCTCAA	CCTGCAACAG	TTTGTTGG	
	90	100	110	120	130	140	150	160	
	TGCATCCAAC	CACCAATTG	CAGCCAGCGC	AGTTTATCAT	CTCACAGACG	CCCCAGGGCC	AGCAGGgtga	gctcc	
C-C-F 177	TGCATCCAAC	CACCAATTG	CAGCCAGCGC	AGTTTATCAT	CTCACAGACG	CCCCAGGGCC	AGCAGG		
C-C-R 178	TGCATCCAAC	CACCAATTG	CAGCCAGCGC	AGTTTATCAT	CTCACAGACG	CCCCAGGGCC	AGCAGG		
P1-F 61	TGCATCCAAC	CACCAATTG	CAGCCAGCGC	AGTTTATCAT	CTCACAGACG	CCCCAGGGCC	AGCAGGGTGA	GCTCCCTCCTT	
P1-R 62	TGCATCCAAC	CACCAATTG	CAGCCAGCGC	AGTTTATCAT	CTCACAGACG	CCCCAGGGCC	AGCAGGGTGA	GCTCCCTCCTT	
P2-F 63	TGCATCCAAC	CACCAATTG	CAGCCAGCGC	AGTTTATCAT	CTCACAGACG	CCCCAGGGCC	AGCAGGGTGA	GCTCCCTCCTT	
P2-R 64	TGCATCCAAC	CACCAATTG	CAGCCAGCGC	AGTTTATCAT	CTCACAGACG	CCCCAGGGCC	AGCAGGGTGA	GCTCCCTCCTT	
P3-F 65	TGCATCCAAC	CACCAATTG	CAGCCAGCGC	AGTTTATCAT	CTCACAGACG	CCCCAGGGCC	AGCAGGGTGA	GCTCCCTCCTT	
P3-R 66	TGCATCCAAC	CACCAATTG	CAGCCAGCGC	AGTTTATCAT	CTCACAGACG	CCCCAGGGCC	AGCAGGGTGA	GCTCCCTCCTT	
P4-F 67	TGCATCCAAC	CACCAATTG	CAGCCAGCGC	AGTTTATCAT	CTCACAGACG	CCCCAGGGCC	AGCAGGGTGA	GCTCCCTCCTT	
P4-R 68	TGCATCCAAC	CACCAATTG	CAGCCAGCGC	AGTTTATCAT	CTCACAGACG	CCCCAGGGCC	AGCAGGGTGA	GCTCCCTCCTT	
	170	180	190	200	210	220	230	240	
	AGAGCTTATT	AGTGGTATAAC	CAAGGGTGT	CGCTGAATGT	TACACATGCA	TGAACACTA	TCATTTGGC	CCTGAACCTA	
P1-F 61	AGAGCTTATT	AGTGGTATAAC	CAAGGGTGT	CGCTGAATGT	TACACATGCA	TAANAGANN	AA-----		
P1-R 62	AGAGCTTATT	AGTGGTATAAC	CAAGGGTGT	CGCTGAATGT	TACACATGCA	TGAACACTA	TCATTTGGC	CCTGAACCTA	
P2-F 63	AGAGCTTATT	AGTGGTATAAC	CAAGGGTGT	CGCTGAATGT	TACACATGCA	TGAACACTA	TCATTTGGC	CCTGAACCTA	
P2-R 64	AGAGCTTATT	AGTGGTATAAC	CAAGGGTGT	CGCTGAATGT	TACACA-GC-	-----	-----	-----	
P3-F 65	AGAGCTTATT	AGTGGTATAAC	CAAGGGTGT	CGCTGAATGT	TACACATGCA	TGAACACTA	TCATTTGGC	CCTGAACCTA	
P3-R 66	AGAGCTTATT	AGTGGTATAAC	CAAGGGTGT	CGCTGAATGT	TACACATGCA	TGAACTAGAN	NCAA-----		
P4-F 67	AGAGCTTATT	AGTGGTATAAC	CAAGGGTGT	CGCTGAATGT	TACACATGCA	TGAACACTA	TCATTTGGC	CCTGAACACTA	
P4-R 68	AGAGCTTATT	AGTGGTATAAC	CAAGGGTGT	CGNNGAA-----	-----	-----	-----	-----	
	250	260	270	280	290	300	310	320	
	TTAAATANNN	NNNNNN	285						
P1-F 61	-----	-----	302						
P1-R 62	-----	-----	302						
P2-F 63	TTAAANNNNN	NNNNNN	288						
P2-R 64	-----	-----	288						
P3-F 65	TTAAANTANNN	NNNNNN	298						
P3-R 66	-----	-----	304						
P4-F 67	TTAANNANNN	NNNNNN	287						
P4-R 68	-----	-----	276						
	330								